PARD6G (PAR-6 gamma): A Comprehensive Review

Introduction

PARD6G encodes Partitioning defective 6 homolog gamma (PAR-6 gamma), a 376-amino acid adapter protein that functions as a critical regulator of cell polarity in human cells. The gene is located on chromosome 18q23 and is a member of the evolutionarily conserved PAR6 family, which includes three paralogs in mammals: PARD6A, PARD6B, and PARD6G [noda-2001-par6-adaptor-abstract]. The PAR (partitioning-defective) genes were originally identified in Caenorhabditis elegans as essential regulators of asymmetric cell division in early embryos, and their mammalian homologs have since been recognized as fundamental components of the cell polarity machinery [noda-2001-par6-adaptor-abstract].

PARD6G functions primarily as a scaffolding protein that nucleates the assembly of the PAR polarity complex, linking small GTPases of the Rho family (particularly Cdc42 and Rac1) to atypical protein kinase C (aPKC) isoforms. This complex plays essential roles in establishing and maintaining apicobasal polarity in epithelial cells, tight junction assembly, neuronal polarization, and centrosome organization. While PARD6G shares core functions with its paralogs, emerging evidence reveals isoform-specific roles, most notably in centrosome biology and tumor suppression [dormoy-2013-par6gamma-centriole-abstract][marques-2016-par6g-cancer-abstract].

Domain Architecture and Structural Basis of Function

PARD6G contains three conserved functional domains that mediate its scaffolding function. The N-terminal region contains a Phox and Bem1p (PB1) domain (residues 18-98), which mediates heterotypic interactions with the PB1 domain of aPKC isoforms PKCiota (PRKCI) and PKCzeta (PRKCZ) [hirano-2005-apkc-par6-pb1-abstract]. The central region harbors a partial or semi-CRIB (Cdc42/Rac interactive binding) motif (residues 134-151), which is required for binding to GTP-loaded Rho GTPases. The third major domain is a PDZ (PSD-95, Discs-large, ZO-1) domain (residues 158-251) that mediates interactions with various binding partners including PALS1 and the C-termini of other polarity proteins [garrard-2003-cdc42-par6-structure-abstract].

The crystal structure of Cdc42 in complex with the GTPase-binding domain of Par6 revealed that the semi-CRIB motif adopts an extended conformation that forms an antiparallel beta-sheet with the beta-2 strand of Cdc42 [garrard-2003-cdc42-par6-structure-abstract]. Remarkably, this interaction also involves the PDZ domain, which serves as a structural scaffold that partially organizes the semi-CRIB motif even in the unbound state. The semi-CRIB and PDZ domains together form a continuous eight-stranded beta-sheet when engaged with Cdc42, burying approximately 1100 square angstroms of surface area and achieving a binding affinity of approximately 50 nM [garrard-2003-cdc42-par6-structure-abstract].

Beyond structural stabilization, Cdc42 binding triggers an allosteric conformational change in the Par6 PDZ domain that enhances its ligand-binding affinity approximately 13-fold [peterson-2004-cdc42-allosteric-abstract]. In the absence of Cdc42, the Par6 PDZ domain adopts a non-canonical conformation with low affinity for C-terminal peptide ligands. Cdc42-GTP binding induces a conformational transition in the CRIB-PDZ module, mediated by a dipeptide switch involving residues L164 and K165, that converts the PDZ to a canonical high-affinity configuration [peterson-2004-cdc42-allosteric-abstract]. This allosteric mechanism enables PARD6G to integrate GTPase signaling with downstream protein-protein interactions.

The interaction between Par6 and aPKC occurs through their respective PB1 domains in a "front-to-back" manner. The crystal structure of the PKCiota-Par6alpha PB1 domain complex at 1.5 angstrom resolution revealed that both PB1 domains adopt a ubiquitin-like fold [hirano-2005-apkc-par6-pb1-abstract]. The PKCiota PB1 domain presents an OPCA (OPR, PC, and AID) motif containing acidic and hydrophobic residues that form salt bridges with a conserved lysine residue on the Par6 PB1 domain. This interaction mode is essential for the assembly of the aPKC-Par6 subcomplex that forms the catalytic core of the PAR polarity complex [hirano-2005-apkc-par6-pb1-abstract].

Subcellular Localization

PARD6G exhibits a complex pattern of subcellular localization that reflects its diverse cellular functions. In polarized epithelial cells, PARD6G localizes to the apical membrane domain and tight junctions, consistent with its role in establishing and maintaining apicobasal polarity [noda-2001-par6-adaptor-abstract]. The protein is also found in the cytoplasm and, under certain conditions, in the nucleus. When co-expressed with aPKC and constitutively active Rac1 in cultured cells, PARD6G co-localizes with these partners to membrane ruffles at the leading edge of migrating cells [noda-2001-par6-adaptor-abstract].

A distinctive feature of PARD6G that distinguishes it from other Par6 family members is its specific localization to the mother centriole within the centrosome [dormoy-2013-par6gamma-centriole-abstract]. The centrosome contains two centrioles of different ages, and the older mother centriole possesses specialized protein appendages that confer unique functions including microtubule organization and ciliogenesis. Dormoy and colleagues demonstrated that PARD6G is a novel component of the mother centriole, and this localization depends on the C-terminal region of the protein (amino acids 259-376) [dormoy-2013-par6gamma-centriole-abstract]. Importantly, centrosomal targeting of PARD6G is independent of intact microtubules, the dynein/dynactin transport complex, and the canonical PAR polarity complex components (Par3 and aPKC), suggesting a distinct targeting mechanism.

The PAR Polarity Complex and Cell Polarity Establishment

PARD6G functions as a central scaffold within the PAR polarity complex, which comprises PAR3 (PARD3), Par6, aPKC, and the small GTPase Cdc42. This complex is evolutionarily conserved from invertebrates to mammals and represents a fundamental mechanism for establishing and maintaining cellular asymmetry [hurd-2003-par6-pals1-abstract]. The PAR complex localizes to the apical domain of polarized epithelial cells, where it excludes basolateral determinants through aPKC-mediated phosphorylation.

The molecular assembly of the PAR complex involves multiple protein-protein interactions. Par6 binds aPKC through PB1 domain heterodimerization, forming a stable core subcomplex. This subcomplex is recruited to the membrane through Cdc42-GTP binding to the Par6 CRIB-PDZ module. Par3 associates with the aPKC-Par6 subcomplex through its interaction with the aPKC kinase domain via a conserved region called CR3. This association is relatively weak and dynamic, allowing for regulated assembly and disassembly of the full PAR complex.

A critical link exists between the PAR complex and the Crumbs polarity complex, mediated by a direct interaction between Par6 and PALS1 (Proteins Associated with Lin Seven 1) [hurd-2003-par6-pals1-abstract]. The amino terminus of PALS1 binds directly to the Par6 PDZ domain, and this interaction is regulated by Cdc42-GTP. Through this mechanism, the transmembrane protein Crumbs can recruit Par6 to the cell surface. Disruption of the Par6-PALS1 interaction perturbs the proper localization of polarity proteins and tight junction markers, demonstrating the functional importance of this connection between polarity complexes [hurd-2003-par6-pals1-abstract].

Role in Tight Junction Assembly

Tight junctions form the apical-most intercellular junctions in epithelial cells and serve dual functions: they create a barrier that controls paracellular permeability and they establish a fence that prevents mixing of apical and basolateral membrane proteins. The PAR complex plays a complex role in tight junction regulation, with evidence for both positive and negative regulatory functions.

Studies by Gao et al. demonstrated that Par6 can negatively regulate tight junction assembly in MDCK epithelial cells [gao-2002-par6-tight-junction-abstract]. Overexpression of Par6 delayed the reassembly of tight junctions following calcium switch, as measured by transepithelial resistance and paracellular permeability assays. The N-terminal fragment of PKCzeta that binds Par6 similarly suppressed tight junction assembly, suggesting that the aPKC-Par6 subcomplex has inhibitory activity. Activated Cdc42 could also disrupt tight junctions, implicating the GTPase-regulated PAR complex in this negative regulatory mechanism [gao-2002-par6-tight-junction-abstract].

These findings suggest a model in which the PAR complex serves a regulatory rather than simply structural role in tight junction dynamics. The complex may function to maintain tight junctions in a dynamic, remodeling-competent state that allows cells to respond to developmental and physiological cues requiring junction plasticity.

TGFbeta Signaling and Epithelial-Mesenchymal Transition

A major pathway through which Par6 proteins regulate epithelial plasticity involves direct phosphorylation by TGFbeta receptors. Ozdamar et al. discovered that Par6 interacts with TGFbeta receptors at tight junctions and is directly phosphorylated by the type II TGFbeta receptor (TbetaRII) at serine 345 [ozdamar-2005-tgfbeta-par6-abstract]. This phosphorylation event is required for TGFbeta-dependent epithelial-to-mesenchymal transition (EMT) in mammary gland epithelial cells.

The mechanism underlying TGFbeta-induced EMT through Par6 involves the E3 ubiquitin ligase Smurf1. Phosphorylation of Par6 at Ser345 promotes its interaction with Smurf1, which then targets the small GTPase RhoA for ubiquitination and proteasomal degradation [ozdamar-2005-tgfbeta-par6-abstract]. Since RhoA activity is required for tight junction maintenance through actin polymerization, its localized degradation results in the dissolution of junctional complexes and the acquisition of mesenchymal characteristics. Importantly, this pathway operates independently of the canonical TGFbeta-Smad transcriptional program, representing a non-transcriptional mechanism for TGFbeta-induced cell plasticity.

This TGFbeta-Par6 axis has significant implications for cancer progression. Phosphorylation of Par6 at Ser345 has been implicated in the invasion and metastatic progression of breast cancer cells and correlates with reduced patient survival. Atypical PKC can also phosphorylate Par6 to drive EMT and increase migratory potential, suggesting that multiple kinases converge on Par6 to regulate epithelial plasticity. These findings position Par6 proteins at a critical node where polarity signaling integrates with growth factor pathways to control cell fate decisions.

Centrosome Function and Ciliogenesis

A major advance in understanding PARD6G-specific functions came from the discovery of its role at the mother centriole. Dormoy et al. found that PARD6G localizes specifically to the mother centriole and controls the protein composition of the centrosome through a Par6alpha-dependent pathway [dormoy-2013-par6gamma-centriole-abstract]. Depletion of PARD6G resulted in dramatic changes in centrosomal protein composition, with loss of numerous proteins including centriolar components (HsSAS-6, STIL, Cep192, Cep152), appendage proteins (Cep164, Cep170, ninein), and centriolar satellite proteins (PCM-1, BBS4, Cep290). Notably, gamma-tubulin complex components remained unaffected.

The functional consequences of PARD6G depletion include severe defects in ciliogenesis, with primary cilia formation decreasing from approximately 80% in controls to approximately 10% in depleted cells [dormoy-2013-par6gamma-centriole-abstract]. Microtubule organization was also disrupted, with 77% of PARD6G-depleted cells displaying disorganized microtubule arrays. During mitosis, 83% of depleted cells exhibited aberrant multipolar spindles at 48 hours post-depletion. Cell migration was impaired due to defective centrosome reorientation in wound-healing assays.

Mechanistically, PARD6G controls centrosomal protein composition by regulating the association of Par6alpha and p150Glued (a dynactin subunit) with the centrosome [dormoy-2013-par6gamma-centriole-abstract]. PARD6G interacts specifically with Par6alpha but not Par6beta, and this interaction is critical for the downstream effects on centrosome composition. Importantly, this centrosomal function of PARD6G operates independently of the canonical PAR polarity complex, as depletion of Par3alpha or aPKC isoforms did not affect centrosomal protein composition [dormoy-2013-par6gamma-centriole-abstract].

Signaling Pathways and Regulation of Cell Proliferation

Beyond its structural and organizational roles, PARD6G participates in signaling pathways that regulate cell proliferation, with important implications for cancer biology. Studies by Marques et al. revealed that PARD6G functions as a negative regulator of the phosphatidylinositol 3-kinase (PI3K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt pathway [marques-2016-par6g-cancer-abstract]. Using three-dimensional mammary epithelial organoid cultures, they demonstrated that silencing of PARD6G alone was sufficient to sustain proliferation and prevent epithelial cell cycle restriction.

The signaling mechanism involves regulation of Akt activation at specific phosphorylation sites. PARD6G-deficient acinar structures retained phosphorylation of Akt at serine 473, a modification associated with full kinase activation [marques-2016-par6g-cancer-abstract]. This contrasts with PARD6B-deficient structures, which showed weak phospho-Akt signal that was enhanced by oncogenic Myc activation. These findings suggest that PARD6G normally suppresses Akt pathway activity to maintain epithelial quiescence.

The relationship between Par6 family members and mitogenic signaling pathways exhibits striking isoform specificity. While PARD6G negatively regulates the PI3K/Akt pathway, PARD6B appears to primarily activate the MAPK pathway and promote proliferation [marques-2015-par6-cancer-editorial-abstract]. This functional divergence manifests in opposite mutational patterns in human cancers: PARD6B frequently undergoes amplification and overexpression (particularly in breast cancer), while PARD6G is targeted by loss-of-function mutations including chromosomal deletions and loss of heterozygosity [marques-2016-par6g-cancer-abstract].

Neuronal Polarity

In neurons, the PAR complex including Par6 proteins plays a central role in axon specification and dendrite development [insolera-2011-par-neuronal-polarity-abstract]. As neurons polarize, Par3 and Par6 become selectively enriched at the tip of the future axon. Disruption of this polarized distribution impairs proper axon formation. The Par6-Cdc42/Rac1 interaction is particularly important in this context, as it regulates actin cytoskeleton dynamics at the growth cone.

The neuronal polarity machinery integrates multiple signaling inputs. The PI3K/GSK3beta pathway shows selective activation at the future axon, where elevated PI3K activity suppresses GSK3beta to promote axon elongation. Wnt signaling through Dishevelled associates with the Par3/Par6/aPKC complex and stabilizes aPKC activity. Additionally, TGFbeta receptor II phosphorylates Par6 at serine 345, contributing to axon formation [insolera-2011-par-neuronal-polarity-abstract].

The PAR complex cross-regulates other polarity kinases including Par1 (MARK family kinases) and Par4 (LKB1). aPKC phosphorylates and inhibits MARK2 in developing axons, preventing MARK2-mediated phosphorylation of microtubule-associated proteins like tau [insolera-2011-par-neuronal-polarity-abstract]. This regulation promotes microtubule stability in the axon. The interplay between the PAR complex and MARK kinases represents a conserved mechanism linking polarity signaling to cytoskeletal organization.

Expression Pattern and Tissue Distribution

PARD6G shows broad expression across human tissues with notable enrichment in certain organs. Northern blot analysis originally detected a 4.0-kb transcript at highest levels in adult and fetal kidney [noda-2001-par6-adaptor-abstract]. Additional expression was observed at lower levels in all other tissues examined, indicating widespread expression. More recent transcriptomic data from the Human Protein Atlas indicates enhanced expression in skin, with measurable levels across bone marrow and lymphoid tissues, brain, gastrointestinal tract, kidney, and many other tissues.

The relative expression levels of the three Par6 isoforms vary across tissues and cell types. In breast cancer cell lines, PARD6A and PARD6G are expressed at significantly lower levels compared to PARD6B. In hyperplastic enlarged lobular units of the breast, PARD6B shows overexpression while PARD6A and PARD6G do not, suggesting isoform-specific regulation in preneoplastic tissue changes [marques-2015-par6-cancer-editorial-abstract].

Implications for Human Disease

The tumor suppressor function of PARD6G has significant implications for cancer biology. Analysis of tumor mutation databases reveals frequent loss-of-function alterations affecting PARD6G across multiple epithelial cancer types, including chromosomal losses, deletions, and loss of heterozygosity [marques-2016-par6g-cancer-abstract]. This contrasts sharply with PARD6B, which shows predominantly gain-of-function changes including amplification and overexpression. The opposing mutational landscapes of these paralogs suggest that cancer cells may selectively tune Par6 pathway activity, decreasing PARD6G-mediated growth suppression while increasing PARD6B-mediated proliferative signals.

The centrosomal functions of PARD6G also have disease relevance. Centrosome abnormalities are a hallmark of cancer cells and can drive chromosomal instability through multipolar spindle formation. The finding that PARD6G depletion causes multipolar spindles suggests that loss of PARD6G function could contribute to genomic instability in tumors [dormoy-2013-par6gamma-centriole-abstract]. Additionally, the role of PARD6G in ciliogenesis connects it to ciliopathies, genetic disorders caused by defective cilia function.

Evolutionary Conservation

The PAR proteins constitute one of the most highly conserved polarity networks in metazoan biology. The PAR system was originally identified through genetic screens in Caenorhabditis elegans, where mutations in the par genes cause defects in asymmetric cell division of the one-cell embryo. Homologs of Par6, along with Par3 and aPKC, have been identified in Drosophila, vertebrates, and all other bilateral animals examined, indicating that these proteins were fundamental players in cell polarization mechanisms more than 500 million years ago.

In C. elegans, PAR-6 contains a single PDZ domain and a CRIB-like domain for GTPase binding, similar to its mammalian counterparts. The PAR-3/PAR-6/PKC-3 complex localizes to the anterior cortex of the one-cell embryo and is essential for establishing the anterior-posterior axis. In Drosophila, the Par6 homolog localizes to the apical domain of epithelial cells and is required for both epithelial polarity and asymmetric division of neuroblasts. The core biochemical interactions between Par6, Par3, aPKC, and Cdc42 are preserved across these species, although the specific biological contexts in which they function have diversified.

Despite the strong conservation of core Par6 functions, the expansion to three Par6 paralogs in mammals (PARD6A, PARD6B, PARD6G) has allowed for functional specialization. While the PB1 and PDZ domains show greater than 70% sequence similarity among the three human paralogs, the C-terminal regions diverge substantially. This divergence likely underlies isoform-specific functions such as the unique centrosomal localization of PARD6G mediated by its C-terminal domain. The evolutionary duplication and subsequent specialization of Par6 genes in mammals may have enabled more sophisticated regulation of polarity in the diverse cell types of complex organisms.

Open Questions

Several important questions about PARD6G biology remain to be addressed:

1. Isoform-specific targeting mechanisms: What determines the specific localization of PARD6G to the mother centriole, and why do other Par6 isoforms not share this localization? The C-terminal region that mediates centrosomal targeting differs substantially between Par6 paralogs, but the molecular details of this targeting mechanism are unknown.

2. Functional redundancy versus specificity: To what extent do the three human Par6 paralogs serve redundant versus distinct functions? The centrosomal function appears specific to PARD6G, but the degree of functional overlap in other cellular contexts is unclear.

3. Regulation of PARD6G expression and activity: What mechanisms control PARD6G protein levels and activity in different cellular contexts? Post-translational modifications, protein stability, and transcriptional regulation remain poorly characterized.

4. Integration with other polarity pathways: How does PARD6G coordinate with other polarity complexes (Crumbs, Scribble) in different cellular contexts, and how does loss of PARD6G affect overall polarity network function?

5. Therapeutic implications: Can the tumor suppressor function of PARD6G be exploited therapeutically? Understanding whether PARD6G function can be restored or enhanced in cancers with PARD6G loss could identify new therapeutic strategies.

6. Structural basis of isoform specificity: High-resolution structural information specific to PARD6G is limited. Structural studies could reveal the molecular basis for isoform-specific protein interactions and functions.

References

• noda-2001-par6-adaptor-abstract: Noda Y, Takeya R, Ohno S, Naito S, Ito T, Sumimoto H. Human homologues of the Caenorhabditis elegans cell polarity protein PAR6 as an adaptor that links the small GTPases Rac and Cdc42 to atypical protein kinase C. Genes to Cells. 2001 Feb;6(2):107-19. DOI: 10.1046/j.1365-2443.2001.00404.x. PMID: 11260256.

• dormoy-2013-par6gamma-centriole-abstract: Dormoy V, Tormanen K, Sütterlin C. Par6gamma is at the mother centriole and controls centrosomal protein composition through a Par6alpha-dependent pathway. J Cell Sci. 2013 Feb 1;126(Pt 3):860-70. DOI: 10.1242/jcs.121186. PMID: 23264737. PMCID: PMC3619814.

• marques-2016-par6g-cancer-abstract: Marques E, Englund JI, Tervonen TA, Virkunen E, Laakso M, Myllynen M, Mäkelä A, Ahvenainen M, Lepikhova T, Monni O, Hautaniemi S, Klefström J. Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers. Oncogene. 2016 Mar 17;35(11):1386-98. DOI: 10.1038/onc.2015.196. PMID: 26073086. PMCID: PMC4800288.

• garrard-2003-cdc42-par6-structure-abstract: Garrard SM, Capaldo CT, Gao L, Rosen MK, Macara IG, Tomchick DR. Structure of Cdc42 in a complex with the GTPase-binding domain of the cell polarity protein, Par6. EMBO J. 2003 Mar 3;22(5):1125-33. DOI: 10.1093/emboj/cdg110. PMID: 12606577. PMCID: PMC150343. PDB: 1NF3.

• peterson-2004-cdc42-allosteric-abstract: Peterson FC, Penkert RR, Volkman BF, Prehoda KE. Cdc42 regulates the Par-6 PDZ domain through an allosteric CRIB-PDZ transition. Mol Cell. 2004 Mar 12;13(5):665-76. DOI: 10.1016/s1097-2765(04)00086-3. PMID: 15023337.

• hirano-2005-apkc-par6-pb1-abstract: Hirano Y, Yoshinaga S, Takeya R, Suzuki NN, Horiuchi M, Kohjima M, Sumimoto H, Inagaki F. Structure of a cell polarity regulator, a complex between atypical PKC and Par6 PB1 domains. J Biol Chem. 2005 Mar 11;280(10):9653-61. DOI: 10.1074/jbc.M409823200. PMID: 15590654. PDB: 1WMH.

• hurd-2003-par6-pals1-abstract: Hurd TW, Gao L, Roh MH, Macara IG, Margolis B. Direct interaction of two polarity complexes implicated in epithelial tight junction assembly. Nat Cell Biol. 2003 Feb;5(2):137-42. DOI: 10.1038/ncb923. PMID: 12545177.

• gao-2002-par6-tight-junction-abstract: Gao L, Joberty G, Macara IG. Assembly of epithelial tight junctions is negatively regulated by Par6. Curr Biol. 2002 Feb 5;12(3):221-5. DOI: 10.1016/s0960-9822(01)00663-7. PMID: 11839275.

• insolera-2011-par-neuronal-polarity-abstract: Insolera R, Chen S, Shi SH. Par proteins and neuronal polarity. Dev Neurobiol. 2011 Jun;71(6):483-94. DOI: 10.1002/dneu.20867. PMID: 21557502. PMCID: PMC3153582.

• marques-2015-par6-cancer-editorial-abstract: Marques E, Klefström J. Par6 family proteins in cancer. Oncoscience. 2015 Nov;2(11):894-5. DOI: 10.18632/oncoscience.255. PMID: 26909361. PMCID: PMC4675776.

• ozdamar-2005-tgfbeta-par6-abstract: Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005 Mar 11;307(5715):1603-9. DOI: 10.1126/science.1105718. PMID: 15761148.

Citations

1. dormoy-2013-par6gamma-centriole-abstract.md
2. dormoy-2013-par6gamma-centriole-summary.md
3. gao-2002-par6-tight-junction-abstract.md
4. garrard-2003-cdc42-par6-structure-abstract.md
5. garrard-2003-cdc42-par6-structure-summary.md
6. hirano-2005-apkc-par6-pb1-abstract.md
7. hirano-2005-apkc-par6-pb1-summary.md
8. hurd-2003-par6-pals1-abstract.md
9. insolera-2011-par-neuronal-polarity-abstract.md
10. marques-2015-par6-cancer-editorial-abstract.md
11. marques-2016-par6g-cancer-abstract.md
12. marques-2016-par6g-cancer-summary.md
13. noda-2001-par6-adaptor-abstract.md
14. noda-2001-par6-adaptor-summary.md
15. ozdamar-2005-tgfbeta-par6-abstract.md
16. peterson-2004-cdc42-allosteric-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity check: The requested target is human PARD6G (PAR-6 gamma), UniProt Q9BYG4. Literature on human PAR-6 proteins consistently describes PAR-6 family members as PB1- and PDZ-domain scaffold/adaptor proteins that partner with atypical PKCs (aPKC/PRKCI or PRKCZ) and CDC42 in the Par3–Par6–aPKC complex. Mechanistic and structural data cited below align with this family/domain architecture and function, supporting that PARD6G belongs to the PAR-6 family with PB1 and PDZ domains and a CRIB–PDZ regulatory module characteristic of PAR-6 proteins (human isoform-specific studies are sparse, so several findings are inferred from conserved PAR-6 mechanisms) (vargas2023insightsintothea pages 23-27, vargas2023insightsintothe pages 23-27, vargas2023insightsintothe pages 112-114, vargas2023insightsintothea pages 112-114).

Key concepts and definitions (current understanding)
- Molecular identity and domains: PAR-6 proteins (including human PARD6G) are polarity adaptors with an N‑terminal PB1 domain that heterodimerizes with the PB1 of aPKC and a C‑terminal CRIB–PDZ module that binds CDC42-GTP and PDZ ligands. This architecture enables assembly of the Par3–Par6–aPKC complex and integration of small GTPase inputs to control apical polarity. A second, lower-affinity interface has been mapped where the Par‑6 CRIB‑PDZ region can directly engage the aPKC kinase domain region (KD‑PBM), complementing the canonical PB1–PB1 interaction (Kd ~20 µM measured biochemically), providing mechanistic basis for Par‑6 modulation of aPKC (see below) (vargas2023insightsintothea pages 23-27, vargas2023insightsintothe pages 23-27, vargas2023insightsintothea pages 32-36, vargas2023insightsintothe pages 32-36).
- Core binding partners and assemblies: PAR-6 binds aPKC (PRKCI/PRKCZ) via PB1–PB1, and binds CDC42‑GTP via the CRIB–PDZ module. PAR-6 and aPKC function within a larger Par network with PAR‑3 and apical determinants such as Crumbs (CRB3), with interactions regulated by CDC42 and PDZ ligands. These assemblies localize to the apical cortex and tight junction region in epithelia to scaffold aPKC activity that enforces apical identity by excluding basolateral factors (vargas2023insightsintothe pages 112-114, vargas2023insightsintothea pages 112-114, vargas2023insightsintothe pages 23-27).

Recent developments and latest research (2023–2024+; mechanistic highlights)
- Dual-mode Par‑6:aPKC contacts and allosteric regulation (biochemical reconstitution, 2023): Purified-component assays mapped two contacts: (1) PB1–PB1 (Par‑6 PB1 ↔ aPKC PB1‑C1) and (2) CRIB‑PDZ to the aPKC KD‑PBM region. The CRIB‑PDZ–KD‑PBM interaction can displace the aPKC PB1‑C1 regulatory module from the kinase domain/autoinhibitory state, proposing a route by which Par‑6 relieves aPKC autoinhibition; this C‑terminal contact is modulated by CDC42 and PDZ‑ligand engagement, rationalizing context-dependent observations that Par‑6 can inhibit or activate aPKC (Kd ~20 µM for CRIB‑PDZ:KD binding) (vargas2023insightsintothea pages 32-36, vargas2023insightsintothe pages 44-49, vargas2023insightsintothe pages 32-36).
- Structural capture–release model for Par6–aPKC substrate handling (2025; accepted 2024): Cryo‑EM structure of human aPKCι–Par6α with full-length Llgl1 shows a tripartite complex that traps a phosphorylated Llgl1 intermediate (pS663) bridging aPKC and Par‑6, impeding further phosphorylation. Disruption of the Lgl–aPKC interface impedes phosphorylation, while disrupting the Lgl–Par‑6 PDZ contact promotes complex dissociation and completion of multisite phosphorylation. The authors propose a Par‑6 PDZ–regulated capture‑and‑release mechanism in which binding by CDC42‑GTP and apical Crumbs promotes disassembly and substrate release, linking CDC42/Crumbs inputs to spatial control of aPKC activity in polarized membrane domains (URL: https://doi.org/10.1038/s41594-024-01425-0) (earl2025capturemutualinhibition pages 1-2).

Subcellular localization and functional roles
- Apical cortex/tight junctions in epithelia: CDC42‑GTP engagement of PAR‑6 CRIB–PDZ promotes apical membrane recruitment and tight-junction enrichment of the Par6–aPKC module; PAR‑3 scaffolding and apical determinants contribute to localization. At the apical cortex, aPKC phosphorylates and excludes basolateral substrates (e.g., LGL), reinforcing apico–basal polarity (vargas2023insightsintothea pages 112-114, vargas2023insightsintothe pages 23-27, earl2025capturemutualinhibition pages 1-2).
- Epithelial polarity and tight junction assembly: The Par3–Par6–aPKC complex is required for apico–basal polarity establishment and tight-junction organization; mechanistic details of Par‑6 regulation of aPKC help explain how signaling and assembly are coupled to junctional localization (vargas2023insightsintothea pages 112-114, vargas2023insightsintothe pages 23-27, vargas2023insightsintothe pages 44-49).
- Front–rear polarity and cell migration: The Par complex integrates CDC42 signaling to recruit and regulate aPKC during cell polarization; biochemical work and network logic from recent analyses emphasize CDC42- and PDZ‑ligand–dependent control of Par6–aPKC assembly and activity, consistent with roles in leading-edge signaling in migrating cells (vargas2023insightsintothe pages 112-114, vargas2023insightsintothea pages 112-114, vargas2023insightsintothe pages 23-27).

Pathways and mechanism of action
- Upstream regulation: CDC42‑GTP binds the Par‑6 CRIB–PDZ module, causing conformational changes that modulate PDZ ligand binding (e.g., Crumbs) and influence the CRIB‑PDZ interaction with the aPKC kinase domain region, thereby affecting aPKC autoinhibition and activation. PAR‑3 provides additional scaffolding and can modulate aPKC substrate access (context-dependent inhibitory effects reported for PAR‑3 CR3-flanking regions) (vargas2023insightsintothe pages 112-114, vargas2023insightsintothea pages 112-114, vargas2023insightsintothea pages 23-27, vargas2023insightsintothe pages 23-27).
- Catalytic output: aPKC in the complex phosphorylates polarity substrates (e.g., LGL), driving their apical exclusion and domain segregation. The cryo‑EM capture–release mechanism shows aPDZ‑regulated kinetic control over multisite phosphorylation and spatial substrate handling, coordinated by CDC42/Crumbs inputs (earl2025capturemutualinhibition pages 1-2).

Disease associations and real-world relevance
- Imprinting/epigenetic regulation at the PARD6G locus: A case report of complete paternal isodisomy of chromosome 18 identified hypomethylation/demethylation of the PARD6G‑AS1 promoter, consistent with parent‑of‑origin methylation (maternal imprint) at this locus; the authors discuss potential phenotypic influence of altered methylation at PARD6G‑AS1 in the clinical presentation (arthrogryposis), and summarize broader evidence that PARD6G/PARD6G‑AS1 carries imprinting marks in human tissues (URL: https://doi.org/10.3389/fgene.2023.1297754; published Dec 2023) (moch2023casereportcomplete pages 6-6, moch2023casereportcomplete pages 4-6).
- Cancer relevance (current evidence limits): Large-scale, isoform‑specific cancer statistics for PARD6G were not found in the retrieved 2023–2025 sources. Nonetheless, the mechanistic literature demonstrates that PAR‑6–aPKC signaling governs epithelial polarity and apical junctions, processes frequently perturbed in carcinomas. The new structural mechanism for Par6–aPKC substrate capture and CDC42/Crumbs‑regulated release provides a rationale for how dysregulation could mispattern apical–basal identity in disease. Where PARD6G-specific data are limited, functional inference rests on conserved domain architecture and shared interactions among human PAR‑6 isoforms (earl2025capturemutualinhibition pages 1-2, vargas2023insightsintothea pages 112-114, vargas2023insightsintothe pages 23-27).

Expert opinions and network logic (recent reviews/analyses)
- Recent biochemical and conceptual syntheses emphasize: (i) multiple, cooperative Par‑6:aPKC contacts (PB1–PB1 and CRIB‑PDZ ↔ aPKC KD‑PBM) that tune aPKC autoinhibition and catalytic output; (ii) allosteric integration of CDC42‑GTP and PDZ ligands (e.g., Crumbs) in controlling Par6–aPKC assembly, localization, and activity; and (iii) dynamic cycling between distinct Par assemblies (with PAR‑3 and apical determinants) underlying robust polarity establishment. These expert perspectives provide a coherent framework for how Par6‑centered scaffolding establishes and maintains apical polarity in human cells (vargas2023insightsintothea pages 32-36, vargas2023insightsintothe pages 112-114, vargas2023insightsintothea pages 112-114, vargas2023insightsintothe pages 44-49).

Relevant statistics and data points from recent studies
- Affinity of the newly described Par‑6 CRIB‑PDZ interaction with the aPKC KD‑PBM region is reported at Kd ~20 µM in pull‑down/biochemical assays with purified proteins, highlighting a low‑affinity but functionally significant regulatory contact that can be missed without targeted constructs (vargas2023insightsintothea pages 32-36, vargas2023insightsintothe pages 32-36).
- The cryo‑EM structure delineates a phosphorylated Llgl1 pS663 intermediate held within the Par6–aPKC complex; mutational disruptions at either the Llgl1–aPKC or Llgl1–Par6 PDZ interfaces alter complex assembly and phosphorylation progression, providing structure–function evidence for a PDZ‑regulated capture–release cycle coordinated by CDC42/Crumbs (doi: 10.1038/s41594-024-01425-0) (earl2025capturemutualinhibition pages 1-2).
- Clinical epigenetics: Hypomethylation/demethylation at PARD6G‑AS1 accompanying paternal iUPD18 in a patient underscores parent‑of‑origin methylation control at the locus and the potential for imprinting perturbations to contribute to disease phenotypes (doi: 10.3389/fgene.2023.1297754) (moch2023casereportcomplete pages 6-6, moch2023casereportcomplete pages 4-6).

Notes on evidence scope
- Direct, isoform‑specific functional studies on human PARD6G (PAR‑6γ) remain limited compared to PAR‑6α/β; however, the defining PB1 and CRIB‑PDZ domains, the conserved aPKC and CDC42 interactions, and their roles in the Par complex are shared across human PAR‑6 proteins. Accordingly, we infer PARD6G function from conserved mechanisms, highlighting where findings derive from PAR‑6 family/complex data in human systems (vargas2023insightsintothea pages 23-27, vargas2023insightsintothe pages 23-27, vargas2023insightsintothea pages 112-114).

Embedded key sources (with URLs where available)
| Citation (authors, title) (context) | Year | Topic / Key Finding | Venue | URL / DOI |
|---|---:|---|---|---|
| Vargas E., "Insights Into the Regulation of aPKC Polarity Through Protein-Protein Interactions" (vargas2023insightsintothea pages 32-36) | 2023 | Biochemical mapping of Par-6:aPKC contacts — PB1–PB1 and a novel CRIB‑PDZ → aPKC KD‑PBM interaction; CRIB‑PDZ regulation by Cdc42 and PDZ ligands; mechanistic basis for Par‑6 modulation of aPKC and apical polarity context. | Unknown journal | N/A |
| Earl CP, Cobbaut M, Barros‑Carvalho A, Ivanova ME, Briggs DC, Morais‑de‑Sá E, Parker PJ, McDonald NQ., "Capture, mutual inhibition and release mechanism for aPKC–Par6 and its multisite polarity substrate Lgl" (earl2025capturemutualinhibition pages 1-2) | 2025 | Cryo‑EM structure of human aPKCι–Par6α–Llgl1 tripartite complex; proposes Par6‑PDZ–regulated capture‑and‑release model that traps a phosphorylated Lgl intermediate and requires Cdc42/Crumbs for complex disassembly. | Nature Structural & Molecular Biology | https://doi.org/10.1038/s41594-024-01425-0 |
| Moch J., Radtke M., Gburek‑Augustat J., et al., "Case report: Complete paternal isodisomy on chromosome 18 induces methylation changes in PARD6G‑AS1 promotor in a case with arthrogryposis" (moch2023casereportcomplete pages 6-6) | 2023 | Reports hypomethylation/demethylation of the PARD6G‑AS1 promoter associated with paternal isodisomy 18; documents imprinting at the PARD6G locus and potential phenotype relevance. | Frontiers in Genetics | https://doi.org/10.3389/fgene.2023.1297754 |

Table: Compact table summarizing three key 2023–2025 papers on Par‑6/PARD6 relevant to human PARD6G, showing biochemical, structural, and epigenetic findings and providing DOIs/URLs where available.

Conclusion
Human PARD6G encodes a PAR‑6 family polarity adaptor with PB1 and CRIB‑PDZ domains that scaffold aPKC and CDC42 within the Par3–Par6–aPKC complex at the apical cortex/tight junctions. Recent biochemical and structural studies reveal dual Par‑6:aPKC interfaces and a Par6‑PDZ–regulated capture–release mechanism for aPKC substrates (e.g., LGL) that is coordinated by CDC42 and Crumbs, offering a detailed molecular basis for how PAR‑6 directs aPKC localization and catalytic output to establish apico–basal polarity. Although PARD6G‑specific disease statistics are sparse, imprinting at the PARD6G/PARD6G‑AS1 locus is documented, and the central role of the Par6–aPKC module in epithelial polarity and junctional organization provides a compelling mechanistic link to disease contexts where polarity is disrupted (vargas2023insightsintothea pages 23-27, vargas2023insightsintothe pages 23-27, vargas2023insightsintothea pages 32-36, vargas2023insightsintothe pages 44-49, earl2025capturemutualinhibition pages 1-2, vargas2023insightsintothea pages 112-114, moch2023casereportcomplete pages 6-6, moch2023casereportcomplete pages 4-6).

References

1. (vargas2023insightsintothea pages 23-27): E Vargas. Insights into the regulation of apkc polarity through protein-protein interactions. Unknown journal, 2023.

2. (vargas2023insightsintothe pages 23-27): E Vargas. Insights into the regulation of apkc polarity through protein-protein interactions. Unknown journal, 2023.

3. (vargas2023insightsintothe pages 112-114): E Vargas. Insights into the regulation of apkc polarity through protein-protein interactions. Unknown journal, 2023.

4. (vargas2023insightsintothea pages 112-114): E Vargas. Insights into the regulation of apkc polarity through protein-protein interactions. Unknown journal, 2023.

5. (vargas2023insightsintothea pages 32-36): E Vargas. Insights into the regulation of apkc polarity through protein-protein interactions. Unknown journal, 2023.

6. (vargas2023insightsintothe pages 32-36): E Vargas. Insights into the regulation of apkc polarity through protein-protein interactions. Unknown journal, 2023.

7. (vargas2023insightsintothe pages 44-49): E Vargas. Insights into the regulation of apkc polarity through protein-protein interactions. Unknown journal, 2023.

8. (earl2025capturemutualinhibition pages 1-2): Christopher P. Earl, Mathias Cobbaut, André Barros-Carvalho, Marina E. Ivanova, David C. Briggs, Eurico Morais-de-Sá, Peter J. Parker, and Neil Q. McDonald. Capture, mutual inhibition and release mechanism for apkc–par6 and its multisite polarity substrate lgl. Nature Structural & Molecular Biology, Jan 2025. URL: https://doi.org/10.1038/s41594-024-01425-0, doi:10.1038/s41594-024-01425-0. This article has 7 citations and is from a highest quality peer-reviewed journal.

9. (moch2023casereportcomplete pages 6-6): Johanna Moch, Maximilian Radtke, Janina Gburek-Augustat, Maike Karnstedt, Senta Schönnagel, Stephan H. Drukewitz, Laura Pilgram, Julia Hentschel, and Isabell Schumann. Case report: complete paternal isodisomy on chromosome 18 induces methylation changes in pard6g-as1 promotor in a case with arthrogryposis. Frontiers in Genetics, Dec 2023. URL: https://doi.org/10.3389/fgene.2023.1297754, doi:10.3389/fgene.2023.1297754. This article has 1 citations and is from a peer-reviewed journal.

10. (moch2023casereportcomplete pages 4-6): Johanna Moch, Maximilian Radtke, Janina Gburek-Augustat, Maike Karnstedt, Senta Schönnagel, Stephan H. Drukewitz, Laura Pilgram, Julia Hentschel, and Isabell Schumann. Case report: complete paternal isodisomy on chromosome 18 induces methylation changes in pard6g-as1 promotor in a case with arthrogryposis. Frontiers in Genetics, Dec 2023. URL: https://doi.org/10.3389/fgene.2023.1297754, doi:10.3389/fgene.2023.1297754. This article has 1 citations and is from a peer-reviewed journal.

Citations

1. earl2025capturemutualinhibition pages 1-2
2. vargas2023insightsintothea pages 32-36
3. moch2023casereportcomplete pages 6-6
4. vargas2023insightsintothea pages 23-27
5. vargas2023insightsintothe pages 23-27
6. vargas2023insightsintothe pages 112-114
7. vargas2023insightsintothea pages 112-114
8. vargas2023insightsintothe pages 32-36
9. vargas2023insightsintothe pages 44-49
10. moch2023casereportcomplete pages 4-6
11. https://doi.org/10.1038/s41594-024-01425-0
12. https://doi.org/10.3389/fgene.2023.1297754;
13. https://doi.org/10.3389/fgene.2023.1297754
14. https://doi.org/10.1038/s41594-024-01425-0,
15. https://doi.org/10.3389/fgene.2023.1297754,

Overview of PARD6G and the PAR6 Family

PARD6G (Par6γ) is a human gene encoding the partitioning-defective 6 homolog gamma protein, also called PAR6 gamma or PAR6D (www.ncbi.nlm.nih.gov). It belongs to the PAR6 family of polarity-regulating adapter proteins, which were first identified in C. elegans as key determinants of asymmetric cell division (the “partitioning-defective” genes) (en.wikipedia.org). Like other PAR6 isoforms (Par6α/PARD6A and Par6β/PARD6B), the Par6γ protein contains several conserved domains: an N-terminal PB1 (OPR) domain, a PDZ domain, and a semi-CRIB domain (en.wikipedia.org). The PB1 domain (Phox/Bem1-type) mediates heterodimerization with other PB1-domain proteins (notably the atypical PKC kinases), while the PDZ domain (PSD95/Discs-large/ZO-1) enables Par6 to scaffold with partners like PAR3 (v21.proteinatlas.org). The “semi-CRIB” region (Cdc42/Rac interactive binding) allows Par6γ to bind active Rho family GTPases (e.g. Cdc42 and Rac1) (en.wikipedia.org). Through these modules, PARD6G’s protein product functions as an adaptor/scaffold that links small GTPases (Cdc42/Rac) to atypical PKC (aPKC) kinases within larger polarity complexes (v21.proteinatlas.org). This molecular architecture is central to its role in cell polarity and signaling.

Key Functional Definition: Par6γ is a regulatory scaffold protein involved in establishing cell polarity and oriented cell division. According to UniProt/Swiss-Prot and expert databases, PARD6G is “an adapter protein involved in asymmetrical cell division and cell polarization processes”, potentially playing a role in forming epithelial tight junctions (v21.proteinatlas.org) (www.genecards.org). In essence, Par6γ does not act as an enzyme or structural filament itself; rather, it organizes signaling complexes at specific cell locations. By binding partners like PAR3 (PARD3) and aPKC, Par6γ helps define the apical membrane domain of epithelial cells and links polarity cues from Rho GTPases to downstream effectors (v21.proteinatlas.org). This function is conserved across species – for example, a seminal Nature Cell Biology study demonstrated that Par6 proteins bridge PAR3 and aPKC to the GTP-bound form of CDC42, anchoring the kinase to precise cortical sites (en.wikipedia.org). Through such interactions, Par6γ orchestrates where and when aPKC phosphorylates targets, thereby guiding processes like junction assembly, cytoskeletal reorganization, and cell-fate asymmetry. In summary, PARD6G encodes a polarity complex scaffold critical for proper cellular orientation and signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Domain Structure and Molecular Interactions

Par6γ’s multi-domain structure enables specific protein–protein interactions that underlie its scaffolding function. At the N-terminus, Par6γ contains a PB1 domain (also known historically as an OPR domain) (en.wikipedia.org). This PB1 domain allows Par6γ to heterodimerize with the PB1 domains of atypical PKC isoforms (such as PKCζ or PKCλ/ι) (en.wikipedia.org). Through PB1-mediated binding, Par6γ directly tethered aPKC to the polarity complex, regulating its localization and activity. The PB1 interaction is critical: disrupting the PB1 domain prevents Par6 from binding aPKC and impairs polarity signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For instance, in zebrafish pard6γb mutants, restoring the PB1 (aPKC-binding) domain is essential to rescue normal function in neural tube development (pmc.ncbi.nlm.nih.gov).

Adjacent to the PB1 domain, Par6γ harbors a PDZ domain, a modular interaction domain commonly binding C-terminal motifs of partner proteins. In the canonical Par polarity complex, Par6’s PDZ domain binds a C-terminal PDZ-binding motif of PAR3 (another partitioning-defective protein) (en.wikipedia.org). This PDZ-mediated link is what couples Par6γ (with aPKC attached) to the PAR3 scaffold at the cell cortex. Notably, Par6 PDZ domains can also engage other polarity factors – for example, Par6 can connect to the Crumbs/PALS1/PATJ complex via a PDZ-binding motif (the KPLG sequence) that binds PALS1 (MPP5) (pmc.ncbi.nlm.nih.gov). This ability to interface with the Crumbs complex underscores Par6γ’s central role coordinating multiple polarity modules. Finally, Par6γ includes a semi-CRIB domain (a partial Cdc42/Rac interactive binding sequence) overlapping the PDZ or C-terminus (en.wikipedia.org). This region specifically binds the active (GTP-bound) forms of Rho-family GTPases like CDC42, RAC1, and related proteins (e.g. TC10/RhoQ) (en.wikipedia.org). Through this interaction, Par6γ is recruited to sites of active CDC42 at the cell membrane, which often mark the nascent apical pole or leading edge of the cell (en.wikipedia.org). The Par6γ–CDC42 interaction is pivotal for polarity signaling – it essentially links external or upstream polarity cues (small GTPase activation) to the assembly of the PAR3/PAR6/aPKC complex at the correct location (v21.proteinatlas.org). In support of this, mutational analyses in model organisms have shown that the CRIB (CDC42-binding) motif of Par6γ is required for its function in epithelial morphogenesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Key molecular partners of Par6γ include:
- PAR3 (PARD3) – a scaffold protein that localizes to tight junctions and cell cortex; Par6γ’s PDZ domain binds PAR3, linking Par6γ–aPKC to PAR3’s complex (v21.proteinatlas.org).
- aPKC (PKCζ, PKCλ/ι) – atypical protein kinase C isoforms; Par6γ’s PB1 domain forms a heterodimer with aPKC PB1, anchoring the kinase into the Par complex (v21.proteinatlas.org). This interaction positions aPKC to phosphorylate downstream targets (such as PAR3 or lateral domain proteins) and is essential for polarity establishment.
- CDC42 and RAC1 – small Rho-family GTPases; GTP-bound CDC42 or Rac1 directly bind Par6γ (via the CRIB region), recruiting the Par6γ–PAR3–aPKC complex to specific membrane locales (en.wikipedia.org). Active CDC42 effectively “activates” the Par complex; in many systems, CDC42-Par6 binding relieves an autoinhibition of aPKC, triggering localized kinase activity (en.wikipedia.org). This is crucial for events like asymmetric cell division (e.g., polarizing the mitotic spindle) and leading edge dynamics in migrating cells.
- RhoQ (TC10) – another Rho GTPase; Par6γ (like Par6β) can also interact with TC10, suggesting broad binding to several polarity-related GTPases (en.wikipedia.org).
- PALS1 (MPP5) and Crumbs – via Par6γ’s PDZ domain motif (KPLG in Par6γ), it can bind PALS1, which in turn connects to Crumbs, integrating the PAR complex with the Crumbs polarity complex at apical junctions (pmc.ncbi.nlm.nih.gov). This crosstalk is important for tight junction formation and apical membrane identity.
- Other partners: Par6 proteins have been reported to interact with additional signaling molecules. For example, Par6α can bind ECT2 (a RhoGEF) (en.wikipedia.org), linking polarity to regulation of RhoA. Par6γ’s interactome is less characterized in literature, but by homology it may share many interactors with Par6α/β. All Par6 isoforms also indirectly influence cytoskeletal and junctional proteins (E-cadherin, actin regulators) through the aPKC pathway.

Through these interactions, Par6γ acts as a hub, assembling a multi-protein complex (often termed the PAR complex) at the cell cortex (pmc.ncbi.nlm.nih.gov). The integrity of this complex is required for downstream signaling – for instance, if Par6γ fails to recruit aPKC or bind CDC42, the cell cannot properly establish or maintain polarity (pmc.ncbi.nlm.nih.gov). In summary, the domains of Par6γ endow it with the ability to couple the signals from Rho GTPases to the execution machinery of cell polarity (PAR3–aPKC and the actin/tubulin cytoskeleton) (en.wikipedia.org) (pmc.ncbi.nlm.nih.gov). This molecular scaffolding function is fundamental to the biological roles described next.

Role in Cell Polarity and Biological Processes

Par6γ is a core component of the evolutionarily conserved PAR polarity complex, which is essential for a variety of cellular polarization events. In epithelial cells, Par6γ (together with Par3 and aPKC) governs apical–basal polarity, the process by which the “top” (apical surface) and “bottom” (basal surface) of the cell acquire distinct compositions and functions (pmc.ncbi.nlm.nih.gov). The Par3/Par6/aPKC complex localizes to the apical cortex at sites of cell–cell contact, just above the tight junctions (which separate apical and lateral surfaces) (www.ncbi.nlm.nih.gov). By recruiting aPKC to the apical junctional region, Par6γ helps establish the apical membrane domain and promotes the maturation of tight junctions (www.genecards.org) (v21.proteinatlas.org). Experimental evidence shows that loss of Par6 function disrupts tight junction assembly: for example, RNAi knockdown of PARD6 homologs can prevent proper localization of junctional markers and cause epithelial layer disorganization (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Indeed, Par6γ is predicted (from Gene Ontology data and homology) to be active at tight junctions, the apical plasma membrane, and the cell cortex in polarized epithelial cells (www.ncbi.nlm.nih.gov). High-resolution imaging confirms Par6 proteins concentrate at the plasma membrane of cells, especially in polarized epithelia (e.g. at the apical cell–cell contacts) (v21.proteinatlas.org). The Human Protein Atlas identifies PARD6G as localized predominantly to the plasma membrane in human cells (v21.proteinatlas.org), consistent with its role in cortical polarity complexes.

Asymmetric cell division is another key process involving Par6γ. As cells divide, the PAR complex can become enriched on one side of the cell, biasing the mitotic spindle orientation and fate determinants into one daughter cell. Par6γ’s role in this was first exemplified in model organisms: in the one-cell C. elegans embryo, for instance, Par6 (with Par3-aPKC) localizes to the anterior cortex and is indispensable for unequal partitioning of cell-fate factors (www.sciencedirect.com). In mammals, Par6 proteins similarly regulate spindle orientation in stem cells and epithelia. A striking example comes from zebrafish: mutants lacking Pard6γb (a zebrafish homolog of PARD6G) show misoriented spindles during neurulation and abnormal tissue morphology (pmc.ncbi.nlm.nih.gov). Specifically, Pard6γb mutant embryos failed to maintain a single central lumen in the neural tube, instead forming multiple lumens due to loss of coordinated apical polarity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These defects were tied to disrupted apical membrane formation and spindle misorientation – cells lacking Pard6γb could not properly align their division axis, linking Par6 to the centrosome/spindle positioning process (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Consistently, PARD6G is annotated to be involved in the centrosome cycle and regulation of cellular localization, according to predictive databases (www.ncbi.nlm.nih.gov). The ability of Par6γ to influence mitotic spindle orientation is a direct consequence of its polarity function: by defining an apical domain, Par6 (and associated proteins like LGN/NuMA in some systems) helps guide the mitotic apparatus for asymmetric outcome.

Apical domain assembly and cell morphogenesis: Par6γ’s presence is crucial for forming specialized apical structures. In epithelial morphogenesis assays (3D cultures of mammary cells), PARD6G was identified as a necessary gene for normal acinar architecture (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). When PARD6G was silenced in non-transformed mammary organoids, cells failed to exit the cell cycle on schedule and the spherical acinar structures became enlarged and disorganized (pmc.ncbi.nlm.nih.gov). In other words, Par6γ loss led to uncontrolled growth and loss of the symmetric architecture of the epithelial acini (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This phenotype underscores Par6γ’s role in coupling cell polarity to growth arrest and organized tissue structure. Likewise, in zebrafish pard6γb mutants, epithelial tissues like the neural tube and kidneys exhibited polarity defects (e.g. multi-lumen tubules) and differentiation issues (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Altogether, these findings demonstrate that Par6γ is indispensable for maintaining epithelial integrity and architecture, by establishing apico-basal polarity which in turn influences cell proliferation and tissue organization. Par6γ’s involvement extends to neurodevelopment as well: Par3/Par6/aPKC complexes guide processes such as neuronal migration, neurite outgrowth, and synaptic development (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). For example, during neuronal polarization, Par6 (with aPKC) accumulates in the budding axon of a neuron, helping one neurite differentiate into the axon while others become dendrites (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Disruption of Par6 function in neural progenitors can lead to neurodevelopmental defects and has been implicated in neuropsychiatric disorders, emphasizing that its polarity-regulating role is vital in many contexts beyond epithelia (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Cellular localization: Par6γ is an intracellular protein that mainly functions at the cell periphery. It is found in the cytosol and cortical regions of cells, often concentrated where cell-cell or cell-substrate contacts form (www.ncbi.nlm.nih.gov). Par6γ is strongly enriched at the apical cortex in polarized cells – e.g., at the apical junction complex of epithelial cells (where tight junctions reside) (www.ncbi.nlm.nih.gov). Given its binding to membrane-associated small GTPases and to PAR3 (which itself binds junctional adhesion proteins), Par6γ effectively attaches to the plasma membrane at specific spots. The protein has also been detected in other compartments under certain conditions: for instance, large-scale cell atlas projects list Par6γ as present in the nucleus as well (www.ncbi.nlm.nih.gov), though the functional significance of any nuclear pool is not well understood. It’s possible that a fraction of Par6γ (or specific isoform splice variants) shuttle to the nucleus or that overexpression can reveal nuclear localization, but the predominant functional locale is the cell cortex and membrane. In summary, Par6γ carries out its role at the cell periphery – at plasma membrane sites, particularly the apical membrane and junctional regions in polarized cells (www.ncbi.nlm.nih.gov) (v21.proteinatlas.org). This localization is consistent with its job as a polarity scaffold, positioning signaling enzymes and structural proteins at the correct cellular address.

Signaling Pathways and Mechanisms Involving Par6γ

Par6γ functions as a node in multiple signaling pathways that govern cell polarity, cell cycle, and cytoskeletal dynamics. One well-characterized pathway is its interplay with the Rho GTPase signaling cascade. Par6γ, via its CRIB domain, binds activated Cdc42 or Rac1 at the membrane (en.wikipedia.org). This positions Par6γ–aPKC at sites of active Cdc42. Cdc42 is often upstream of polarity establishment; for example, in migrating cells, a Cdc42-Par6-aPKC complex helps define the front of the cell. In epithelia, Cdc42 localized at the developing apical surface recruits Par6/aPKC to initiate apical membrane formation. When Cdc42 binds Par6, it can induce conformational changes that modulate aPKC activity. In fact, Cdc42’s role in Par complex activation is conserved from fly to human: loss of Cdc42 phenocopies loss of Par6 in causing polarity defects (pubmed.ncbi.nlm.nih.gov). Thus, Par6γ is a critical effector of Cdc42, translating Cdc42’s spatial cues into assembly of polarity complexes and targeted phosphorylation events.

Atypical PKC signaling: Once localized by Par6γ, aPKC phosphorylates a suite of substrates that execute polarization. For instance, aPKC can phosphorylate PAR3 (causing PAR3 to dissociate from the tight junction, refining the complex’s composition) and can phosphorylate lateral domain proteins like LGL (Lethal giant larvae) to exclude them from the apical cortex (www.sciencedirect.com). This creates mutually exclusive membrane domains – an apical region with Par3/Par6/aPKC, and a basolateral region with other complexes – establishing polarity. By scaffolding aPKC, Par6γ indirectly controls such phosphorylation events. If Par6γ is absent or not at the membrane, aPKC may mislocalize or remain inactive, leading to polarity loss. The Par6γ–aPKC module is also involved in junctional dynamics and actin remodeling. One notable mechanism is seen during epithelial–mesenchymal transition (EMT) triggered by TGF-β signaling: Par6 (likely Par6α/β in these studies) gets phosphorylated by the TGF-β type II receptor, which enables Par6 to recruit the E3 ubiquitin ligase Smurf1 (www.sciencedirect.com). The Par6–Smurf1 complex then targets the small GTPase RhoA for degradation, causing localized loss of actomyosin contractility at tight junctions (www.sciencedirect.com). This results in the dissolution of tight junctions and loss of apical polarity, a critical early step in EMT when epithelial cells become migratory. In summary, Par6 acts as a key mediator in TGF-β/Smurf1 signaling to downregulate RhoA and promote junction disassembly during EMT (www.sciencedirect.com). This illustrates how Par6γ can integrate with broader signaling networks (here, integrating a growth factor signal to a polarity/cytoskeleton outcome).

Beyond TGF-β, Par6γ influences cell cycle regulatory signaling. Recent research has uncovered a connection between the Par6 complex and the PI3K/Akt pathway, which is a major cell growth and survival signaling cascade. In a 3D mammary epithelial model, loss of PARD6G was found to cause aberrant activation of protein kinase B (Akt), a central growth regulator (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Specifically, PARD6G knockdown led to sustained phosphorylation of Akt at its activating sites (Thr308 and Ser473) even under growth factor–deprived conditions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This was linked to the canonical PI3K–PDK1–Akt pathway: without Par6γ, phosphorylation of Akt by PDK1 was unchecked, resulting in hyperactive Akt signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Mechanistically, Par6γ loss also reduced phosphorylation of PKCζ at its activation loop (pmc.ncbi.nlm.nih.gov), indicating that the Par complex’s activity was compromised. Since aPKC is known to scaffold with and be regulated by PDK1 as well, one hypothesis is that Par6γ normally sequesters or regulates PDK1–aPKC interactions, thereby indirectly restraining Akt activation (Akt requires PDK1 and PIP₃ to be fully active) (pmc.ncbi.nlm.nih.gov). In the absence of Par6γ, PDK1 may more freely activate Akt, bypassing normal polarity-coupled growth suppression. In essence, Par6γ serves as a brake on the PI3K/Akt pro-growth pathway, coupling epithelial structure to cell cycle exit (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This concept is supported by functional studies: cells lacking Par6γ failed to undergo normal cell cycle arrest in 3D culture, but when researchers inhibited PDK1 (upstream of Akt), the uncontrolled proliferation caused by Par6γ loss was partly rescued (pmc.ncbi.nlm.nih.gov). Thus, Par6γ exerts a tumor-suppressive signal by negatively regulating Akt activity via the PAR complex integrity. This finding places Par6γ at an intersection of polarity signaling and classical growth factor signaling.

Other pathways: Par6γ (and its relatives) have been implicated in additional signaling contexts. For example, in neuronal cells, Par6–aPKC can interact with GSK-3β and adenomatous polyposis coli (APC) to regulate microtubule dynamics during axon specification (pmc.ncbi.nlm.nih.gov). In endothelial cells, Par6 is involved in VEGF signaling to modulate cell migration and lumen formation. The Hippo pathway – an important regulator of organ size and growth – is functionally tied to cell polarity proteins as well; disruptions in Par6 can affect Hippo signaling by mislocalizing Hippo components at the cortex (pmc.ncbi.nlm.nih.gov). Indeed, a screen of epithelial structure regulators found that Par6γ and the Hippo kinases both contribute to restricting growth in organoids (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These examples emphasize that Par6γ’s influence extends into many biochemical pathways by virtue of its ability to organize protein complexes at specific cell locations and times. Whenever cell architecture needs to be coordinated with signaling (be it during development, wound healing, or cell migration), Par6γ is often one of the key orchestrators.

Clinical and Real-World Implications of PARD6G Function

Par6γ’s role as a polarity regulator has significant implications in development and disease. Particularly in cancer biology, cell polarity proteins can act as context-dependent tumor suppressors or promoters (pmc.ncbi.nlm.nih.gov). In normal epithelial tissue, proper polarity (organized by Par6γ complexes) keeps cell growth in check and maintains tissue architecture. Loss of polarity is a hallmark of high-grade tumors – cancer cells often exhibit disorganized architecture and uncontrolled proliferation. Given Par6γ’s function in enforcing growth arrest when epithelial structure is intact, it is perhaps not surprising that PARD6G appears to function as a tumor suppressor in certain contexts (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Large-scale cancer genome analyses show that the PARD6G gene is frequently inactivated in multiple epithelial cancers (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In one study analyzing data from The Cancer Genome Atlas and other datasets, PARD6G was found to undergo loss-of-function alterations (chromosomal deletions, loss of heterozygosity, or inactivating mutations) in diverse tumor types, whereas its sister gene PARD6B more often showed amplifications or overexpression in cancers (pmc.ncbi.nlm.nih.gov). This dichotomy suggests that elevated Par6β might benefit some tumors (potentially by aiding invasive behavior), while loss of Par6γ removes restraints on proliferation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The functional studies by Marques et al. support this: silencing PARD6G in mammary organoids led to hyper-proliferation and overgrowth, mimicking a neoplastic phenotype (pmc.ncbi.nlm.nih.gov). The same study reported that PARD6G knockdown alone could drive cells to continue cycling when they should be quiescent, whereas PARD6B knockdown required additional oncogenic signals (like MYC activation) to cause a similar effect (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These results position Par6γ as a stronger enforcer of normal growth limits. Consistently, active Akt signaling was observed in Par6γ-deficient cells even in the absence of growth factors, reinforcing the link between Par6γ loss and a pro-tumorigenic pathway (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). As the authors concluded, “Par6 activity appears to be important for repressive regulation of PI3K/PDK1/Akt-dependent proliferation”, and loss of Par6G unleashes AKT-driven growth signals (pmc.ncbi.nlm.nih.gov). In human tumors, this may translate to a selective pressure to delete or silence PARD6G in order to bypass polarity-dependent growth arrest. Indeed, the PARD6G gene was found to be frequently deleted or downregulated in certain cancers (e.g. subsets of breast, liver, and colon carcinomas) (pmc.ncbi.nlm.nih.gov). Supporting this, Oncogene database analyses (cBioPortal) have identified PARD6G mutations and deletions in patient tumors, consistent with its proposed tumor suppressor role (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). It is noteworthy that PARD6B, in contrast, is sometimes upregulated in cancers (for example, amplified in some colorectal cancers, as an oncogenic driver of MYC signaling) (pmc.ncbi.nlm.nih.gov). These divergent patterns indicate that therapies might need to consider isoform-specific contexts – inhibiting Par6β pathways where it’s oncogenic, while somehow restoring or mimicking Par6γ’s function where its loss drives cancer.

In terms of real-world clinical relevance, polarity proteins like PARD6G are being studied as both biomarkers and therapeutic targets. As a biomarker, loss of PARD6G expression or function might correlate with cancer progression. For instance, analysis from the Human Protein Atlas notes that high PARD6G expression is an unfavorable prognostic marker in liver cancer patients (v21.proteinatlas.org) (this could reflect a subset of tumors where Par6γ upregulation is associated with more aggressive behavior, or perhaps a feedback response in advanced disease; the exact interpretation is still under investigation). Conversely, the absence of Par6γ might mark tumors with a loss of polarity. On the therapeutic front, one strategy is to target the Par6–aPKC interaction in cancers where it’s pathologically activated. In certain aggressive cancers (e.g. some melanomas and breast carcinomas), an atypical PKC/Par6 pathway is hijacked to promote EMT and invasion (en.wikipedia.org). For example, in metastatic melanoma cells, PKC-ι (aPKC lambda/iota) forms a complex with Par6 that drives EMT and cell invasion; inhibiting PKC-ι was shown to reduce Par6 levels, restore E-cadherin at cell junctions, increase RhoA (which stabilizes junctions), and decrease vimentin, thereby reversing EMT markers (en.wikipedia.org). Two novel aPKC inhibitors tested in that context (ACPD and DNDA) effectively suppressed melanoma cell proliferation and EMT, inducing apoptosis (en.wikipedia.org). This indicates that disrupting the Par6–aPKC signaling axis can have anti-tumor effects in cancers dependent on that pathway. While those inhibitors target PKC, not Par6 directly, they underscore a wider concept: the Par6 polarity complex is actionable – it can be modulated to impact cell adhesion and migration in cancer. In the future, targeting Par6γ specifically could be challenging (as scaffold proteins lack easy drug-binding pockets), but understanding its pathway suggests alternative nodes to hit (like PKC-ι, or upstream regulators like TGF-β signaling in EMT contexts).

Another “real-world” application of PARD6G biology is in the field of organ-on-a-chip and 3D culture systems. Polarity proteins are used as readouts for proper tissue organization. In drug testing using organoids or spheroids, researchers often examine Par6/Par3 localization to ensure the model forms realistic architecture. Indeed, the identification of Par6γ as necessary for quiescent, growth-arrested acini in 3D culture (pmc.ncbi.nlm.nih.gov) suggests that measuring PARD6G expression or localization could inform whether an organoid has achieved a differentiated state. Similarly, in regenerative medicine, promoting proper expression of Par6γ might aid the formation of organized epithelial layers. Genetic studies in animals also underscore the physiological importance of PARD6G – for example, mouse models (Mus musculus Pard6g) may exhibit developmental defects if this gene is disrupted (though detailed mouse knockout phenotypes aren’t widely reported, likely due to redundancy with other isoforms). In zebrafish, as discussed, pard6γb mutants provided a real-world demonstration that loss of a Par6 gene leads to multi-lumen organs and polarity defects (pmc.ncbi.nlm.nih.gov). This has relevance to human congenital conditions: defects in cell polarity genes can contribute to developmental disorders and polycystic diseases (where tubules lose their single-lumen structure, somewhat reminiscent of the zebrafish phenotype).

Outside of pathology, PARD6G has been implicated in natural physiological variations and aging. A 2023 cross-species study on aging dogs found that PARD6G exhibits age-associated DNA methylation changes (pmc.ncbi.nlm.nih.gov). In older dogs, the PARD6G gene region was significantly hypomethylated compared to younger dogs (pmc.ncbi.nlm.nih.gov). Since hypomethylation often correlates with increased gene expression, this could suggest that Par6γ expression is upregulated with age, possibly as a response to cellular aging or as part of the aging process in tissues. The study further noted that many genes showing age-dependent methylation (including PARD6G) also have known roles in tumor suppression and differentiation control (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This raises an intriguing point: Par6γ sits at the crossroads of aging and cancer – its regulation might change with age in a way that impacts cancer risk or tissue integrity. In human data, the PARD6G locus also encodes a long non-coding RNA, PARD6G-AS1, which recent analyses have linked to cancer outcomes. For example, in endometrial cancer, hypomethylation of the PARD6G-AS1 lncRNA was associated with higher recurrence risk and metastasis (www.frontiersin.org) (www.frontiersin.org). While that finding pertains to an antisense RNA and not the protein itself, it highlights the broader significance of the PARD6G genomic region in disease. The authors of that 2024 study noted that “PAR6 proteins […] interact with classical cancer driver signaling pathways”, reinforcing that the Par6 family (including Par6γ) is embedded in critical oncogenic networks (www.frontiersin.org).

Expert perspectives: Authorities in cell polarity and cancer research have increasingly recognized PARD6G’s importance. A 2023 review in Life Sciences (Zhang et al.) dedicated to Par6 in tumor development emphasized that Par6 is a “core regulator of cell polarity whose dysregulation is increasingly implicated in tumorigenesis and progression.” (pubmed.ncbi.nlm.nih.gov). Notably, this review highlights the distinct expression patterns of Par6 isoforms (PARD6A, PARD6B, PARD6G) across different cancer types and their divergent clinical implications (pubmed.ncbi.nlm.nih.gov). In other words, experts acknowledge that Par6γ may behave differently from Par6α/β in disease contexts – an insight that matches the data showing Par6γ is lost in cancers whereas Par6β can be upregulated (pmc.ncbi.nlm.nih.gov). The same review elaborates on how Par6 proteins contribute to tumor biology, including interactions with pathways like TGF-β (for EMT), Notch, Wnt, and others that drive tumor progression (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Another commentary by Marques and Klefström (2015) succinctly noted that “many advances in polarity research may have flown under the radar of mainstream cancer biology,” but that recent findings (including their own) “suggest that loss of epithelial integrity and polarity can directly unleash proliferative signals” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Their work essentially positions Par6G as a linchpin linking epithelial architecture to cell-cycle control, such that breaking polarity (via Par6G loss) removes a barrier to cancerous growth (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This paradigm is now gaining traction: maintaining cell polarity is seen as a non-canonical tumor suppressor mechanism (www.nature.com).

From a biomedical research standpoint, the PAR6G gene and its protein product are increasingly studied for their role in disease modeling and therapy. The evidence that Par6γ negatively regulates PI3K/Akt opens the door to exploring it in metabolic diseases or proliferative disorders beyond cancer (e.g., fibrotic diseases where polarity loss occurs). In regenerative medicine, modulating Par6γ might improve the organized growth of tissues. In cancer therapy, components of the Par6γ pathway (like aPKC) are being targeted for drug development – PKC-ι inhibitors are already in early trials for some cancers, based on the rationale that they can interfere with Par6-mediated EMT and invasion.

Recent Developments (2023–2024) and Ongoing Research

Latest research continues to shed light on PARD6G’s function and its broader significance. In the past two years, there has been a focus on how Par6 family proteins influence cancer outcomes and how their regulation is interwoven with epigenetics and cell fate. For example, a Genes (Basel) 2023 study examined aging in dogs and found PARD6G as part of a conserved aging signature, linking its epigenetic changes to age-related transcriptional shifts (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Such findings raise questions about whether PARD6G upregulation in aged tissues might be a compensatory mechanism or a risk factor (since older animals have higher cancer incidence, a deregulation of polarity in aging cells could contribute to tumorigenesis). Another very recent analysis (Frontiers in Genetics, 2025) identified PARD6G-AS1 hypomethylation as a strong predictor of tumor recurrence in a subset of endometrial cancer patients (www.frontiersin.org). Although this involves the non-coding aspect of the locus, it underscores active interest in the PARD6G region as a biomarker.

On the fundamental science side, researchers are delving deeper into isoform-specific roles of Par6. The 2023 review by Zhang et al. not only compiled known mechanisms (TGFβ/Par6/Smurf1, PAR complex in polarity) but also systematically compared PARD6A vs PARD6B vs PARD6G in various tumor databases (pubmed.ncbi.nlm.nih.gov). This kind of analysis is revealing, for instance, that PARD6B is often overexpressed in carcinomas like colorectal or ovarian cancer, whereas PARD6G tends to be downregulated or deleted (pmc.ncbi.nlm.nih.gov). Such divergent patterns might explain why some earlier reports found Par6 as oncogenic (those likely pertained to Par6B or Par6A in certain cancers promoting EMT) whereas newer reports (like Marques et al.) found Par6G as tumor-suppressive (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The field is moving toward appreciating these nuances. This is a recent development because up until the mid-2010s, Par6 isoforms were not always distinguished in studies. Now, tools like isoform-specific antibodies and CRISPR models allow researchers to dissect the unique contributions of PARD6G.

In 2024, we also see continued interest in the role of Par6 complexes in cell migration and invasion. A Nature Communications 2023 article explored how polarity proteins (including Par6/aPKC) contribute to macropinocytosis in pancreatic cancer cells, linking metabolic stress responses to polarity signaling (www.nature.com). While that study focused more on aPKC, it implicitly involves Par6 as an aPKC partner and highlights that polarity complexes have functions even in transformed, migrating cancer cells – influencing how cells internalize nutrients or interact with their environment. Additionally, neuroscience research in 2022–2023 has implicated Par6 complexes in the maintenance of neural stem cell polarity and implications for diseases like brain malformations and neurodegeneration (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This breadth of research – from cancer to aging to neuroscience – reflects Par6γ’s fundamental role and explains the sustained research interest.

Statistics from recent studies: To quantify some of these insights, consider these data points: In the 2016 Oncogene study, PARD6G was found to be mutated or deleted in a significant fraction of analyzed carcinomas – for example, in breast cancer cohorts, PARD6G alterations (chiefly deletions) were observed in a notable subset of cases (pmc.ncbi.nlm.nih.gov). The exact frequency can vary by cancer type (e.g., one analysis showed PARD6G loss in ~10–15% of certain breast and ovarian cancer samples (pmc.ncbi.nlm.nih.gov), whereas PARD6B was amplified in a similar fraction). In the endometrial cancer recurrence study (Front Genet 2025), patients whose tumors had PARD6G-AS1 hypomethylation had significantly worse outcomes, with p = 0.006 for recurrence association (www.frontiersin.org). This suggests the PARD6G locus is statistically robust as a prognostic marker in that context. From the aging dog study: among 15 breeds, PARD6G was consistently identified as age-differentially methylated, showing lower methylation (and presumably higher expression) in older dogs with a significance reported (the data imply a reproducible trend, though an exact p-value wasn’t given in the snippet) (pmc.ncbi.nlm.nih.gov). Lastly, a 2022 analysis of human tumors noted that PARD6G mRNA is downregulated in high-grade tumors compared to normal tissue in certain epithelial cancers (data from TCGA), aligning with the genetic loss data (this is mentioned in the 2023 review abstract that Par6γ has distinct expression patterns in tumors) (pubmed.ncbi.nlm.nih.gov).

In summary, PARD6G/Par6γ is now recognized not only as a fundamental cell polarity regulator but also as a factor in disease pathways. Its primary function is to scaffold and localize signaling molecules (aPKC, PAR3, CDC42, etc.) to establish polarity and oriented cell division. It carries out this function at the cell cortex and apical membrane within cells, playing a crucial role in processes like tight junction formation, epithelial morphogenesis, and asymmetric cell division. Through the Par6γ–aPKC complex, it participates in key signaling pathways (from polarity maintenance to growth factor signaling cross-talk). Recent research (especially in 2023–2024) has highlighted Par6γ’s relevance in cancer, showing that its loss can fuel oncogenic pathways (Akt) while its misregulation can be harnessed as a biomarker. Expert analyses concur that maintaining Par6 function is vital for normal cell homeostasis, and its dysregulation can have pathological consequences (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). As our understanding grows, PARD6G stands out as an exemplar of how cell architecture and signaling are intimately linked – and how a single scaffold protein at the cell’s cortex can influence everything from the microscopic arrangement of junctions to the macroscopic development of tissues and tumors.

Citations:

1. Alliance of Genome Resources (Jul 2025). PARD6G Gene Summary – par-6 family cell polarity regulator gamma (Homo sapiens) (www.ncbi.nlm.nih.gov).
2. UniProtKB/Swiss-Prot (Q9BYG4) via Human Protein Atlas. Protein function and subcellular location for PAR6G_HUMAN (v21.proteinatlas.org) (v21.proteinatlas.org).
3. Wikipedia – PARD6B page (retrieved 15-July-2025). Function and Interactions of Par6β (human PAR6B) (en.wikipedia.org) (en.wikipedia.org).
4. Zhang et al., J. Neurosci. 42(24):4774-4793 (15-Jun-2022). “The Roles of Par3, Par6, and aPKC Polarity Proteins in Neurodevelopment and Neurodegenerative Disorders.” (Review) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
5. Munson et al., Dev. Biol. 324(1):41–54 (2008). “Regulation of neurocoel morphogenesis by Pard6γb.” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
6. Marques et al., Oncogene 35(11):1386–1398 (2016). “Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers.” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
7. Marques & Klefström, Oncoscience 2(11):894–895 (2015). “Par6 family proteins in cancer” (Editorial) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
8. Human Protein Atlas (v21, 2023). PARD6G expression in tissues and cell lines (v21.proteinatlas.org) (v21.proteinatlas.org).
9. GeneCards (accessed Nov 2025). PARD6G Gene – Par6G protein details and UniProt summary (www.genecards.org) (www.genecards.org).
10. Kim et al., Genes (Basel) 14(6):1131 (2023). “Genome-wide integrative transcriptional profiling identifies age-associated signatures in dogs.” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
11. Hong et al., Front. Genet. 16:1569122 (2025). “Integrative analysis of TCGA to predict endometrial cancer recurrence (emphasizing PARD6G-AS1).” (www.frontiersin.org) (www.frontiersin.org).
12. PubMed (PMID: 41110735) – Zhang et al., 2023. “Polarity protein Par6: mechanisms in tumor development and research advances.” (Review abstract) (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).
13. Wikipedia – PARD6A page (retrieved 17-July-2025). Par6α function in EMT and PKC-ι signaling (en.wikipedia.org) (en.wikipedia.org).
14. Ozdamar et al., Science 307(5715):1603–1609 (2005). “Regulation of the polarity protein Par6 by TGF-β receptors controls epithelial cell plasticity.” PMID: 15761148 (Key mechanism: Par6–Smurf1–RhoA in EMT) (www.sciencedirect.com). (Referenced via review snippet)
15. Lee & Vasioukhin, J. Cell Sci. 121:1141–1150 (2008). “Cell polarity and cancer – polarity as a tumor suppressor.” (General background on polarity loss in cancer) (www.nature.com).

Citations

1. AnnotationURLCitation(end_index=271, start_index=183, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=PAR,Expression')
2. AnnotationURLCitation(end_index=548, start_index=473, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=,elegans')
3. AnnotationURLCitation(end_index=857, start_index=743, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=This%20gene%20is%20a%20member,protein%20complex')
4. AnnotationURLCitation(end_index=1228, start_index=1081, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Predicted%20location,i%7D%20Cell%20cycle%2C%20Cell%20division')
5. AnnotationURLCitation(end_index=1458, start_index=1354, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=PARD6B%20has%20been%20shown%20to,RHOQ')
6. AnnotationURLCitation(end_index=1815, start_index=1654, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Protein%20function%20%28UniProt%29,i%7D%20Cell%20cycle%2C%20Cell%20division')
7. AnnotationURLCitation(end_index=2428, start_index=2267, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Protein%20function%20%28UniProt%29,i%7D%20Cell%20cycle%2C%20Cell%20division')
8. AnnotationURLCitation(end_index=2535, start_index=2429, title='PARD6G Gene - GeneCards | PAR6G Protein | PAR6G Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=PARD6G#:~:text=UniProtKB%2FSwiss')
9. AnnotationURLCitation(end_index=3025, start_index=2864, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Protein%20function%20%28UniProt%29,i%7D%20Cell%20cycle%2C%20Cell%20division')
10. AnnotationURLCitation(end_index=3339, start_index=3258, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=,August%202000')
11. AnnotationURLCitation(end_index=3793, start_index=3649, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=The%20Par3%2FPar6%2FaPKC%20protein%20complex%20plays,binding')
12. AnnotationURLCitation(end_index=3956, start_index=3794, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
13. AnnotationURLCitation(end_index=4337, start_index=4223, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=This%20gene%20is%20a%20member,protein%20complex')
14. AnnotationURLCitation(end_index=4565, start_index=4461, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=PARD6B%20has%20been%20shown%20to,RHOQ')
15. AnnotationURLCitation(end_index=4976, start_index=4815, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=multiple%20lumens%20in%20the%20neural,to%20examine%20the%20localization%20and')
16. AnnotationURLCitation(end_index=5139, start_index=4977, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
17. AnnotationURLCitation(end_index=5455, start_index=5293, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
18. AnnotationURLCitation(end_index=5901, start_index=5751, title='PARD6A', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6A#:~:text=This%20gene%20is%20a%20member,different%20isoforms%2C%20have%20been%20characterized')
19. AnnotationURLCitation(end_index=6374, start_index=6212, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
20. AnnotationURLCitation(end_index=6745, start_index=6631, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=This%20gene%20is%20a%20member,protein%20complex')
21. AnnotationURLCitation(end_index=6993, start_index=6889, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=PARD6B%20has%20been%20shown%20to,RHOQ')
22. AnnotationURLCitation(end_index=7264, start_index=7160, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=PARD6B%20has%20been%20shown%20to,RHOQ')
23. AnnotationURLCitation(end_index=7643, start_index=7482, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Protein%20function%20%28UniProt%29,i%7D%20Cell%20cycle%2C%20Cell%20division')
24. AnnotationURLCitation(end_index=7982, start_index=7821, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=multiple%20lumens%20in%20the%20neural,to%20examine%20the%20localization%20and')
25. AnnotationURLCitation(end_index=8145, start_index=7983, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
26. AnnotationURLCitation(end_index=8516, start_index=8355, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Protein%20function%20%28UniProt%29,i%7D%20Cell%20cycle%2C%20Cell%20division')
27. AnnotationURLCitation(end_index=8841, start_index=8680, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Protein%20function%20%28UniProt%29,i%7D%20Cell%20cycle%2C%20Cell%20division')
28. AnnotationURLCitation(end_index=9288, start_index=9184, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=PARD6B%20has%20been%20shown%20to,RHOQ')
29. AnnotationURLCitation(end_index=9534, start_index=9453, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=,August%202000')
30. AnnotationURLCitation(end_index=9941, start_index=9837, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=PARD6B%20has%20been%20shown%20to,RHOQ')
31. AnnotationURLCitation(end_index=10323, start_index=10161, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
32. AnnotationURLCitation(end_index=10663, start_index=10562, title='PARD6A', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6A#:~:text=PARD6A%20has%20been%20shown%20to,8')
33. AnnotationURLCitation(end_index=11257, start_index=11104, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=neurodegenerative%20disorders,functions%20in%20various%20aspects%20of')
34. AnnotationURLCitation(end_index=11605, start_index=11444, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=multiple%20lumens%20in%20the%20neural,to%20examine%20the%20localization%20and')
35. AnnotationURLCitation(end_index=11881, start_index=11800, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=,August%202000')
36. AnnotationURLCitation(end_index=12035, start_index=11882, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=neurodegenerative%20disorders,functions%20in%20various%20aspects%20of')
37. AnnotationURLCitation(end_index=12738, start_index=12556, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=The%20Par3%2FPar6%2FaPKC%20protein%20complex%20plays,in%20mitotic%20spindle%20orientation%20during')
38. AnnotationURLCitation(end_index=13034, start_index=12909, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=Summary%20Predicted%20to%20be%20involved,Expression')
39. AnnotationURLCitation(end_index=13294, start_index=13188, title='PARD6G Gene - GeneCards | PAR6G Protein | PAR6G Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=PARD6G#:~:text=UniProtKB%2FSwiss')
40. AnnotationURLCitation(end_index=13456, start_index=13295, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Protein%20function%20%28UniProt%29,i%7D%20Cell%20cycle%2C%20Cell%20division')
41. AnnotationURLCitation(end_index=13814, start_index=13690, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Par3,overgrowth%20of%20the%20acini%20and')
42. AnnotationURLCitation(end_index=13959, start_index=13815, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=were%20borderline%20hits,structure%20to%20the%20cell%20cycle')
43. AnnotationURLCitation(end_index=14267, start_index=14142, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=Summary%20Predicted%20to%20be%20involved,Expression')
44. AnnotationURLCitation(end_index=14566, start_index=14439, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Subcellular%20summary,bound%20Rho%20small')
45. AnnotationURLCitation(end_index=14802, start_index=14675, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Subcellular%20summary,bound%20Rho%20small')
46. AnnotationURLCitation(end_index=15514, start_index=15331, title='Cell polarity: the ups and downs of the Par6/aPKC complex - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S0959437X03000777#:~:text=Cell%20polarity%3A%20the%20ups%20and,polar%20granules%20to%20the%20posterior')
47. AnnotationURLCitation(end_index=15962, start_index=15791, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=mutant%2C%20representing%20the%20first%20known,membranes%20are%20reduced%2C%20but%20not')
48. AnnotationURLCitation(end_index=16309, start_index=16138, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=mutant%2C%20representing%20the%20first%20known,membranes%20are%20reduced%2C%20but%20not')
49. AnnotationURLCitation(end_index=16471, start_index=16310, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=multiple%20lumens%20in%20the%20neural,to%20examine%20the%20localization%20and')
50. AnnotationURLCitation(end_index=16867, start_index=16696, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=mutant%2C%20representing%20the%20first%20known,membranes%20are%20reduced%2C%20but%20not')
51. AnnotationURLCitation(end_index=17030, start_index=16868, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
52. AnnotationURLCitation(end_index=17307, start_index=17182, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=Summary%20Predicted%20to%20be%20involved,Expression')
53. AnnotationURLCitation(end_index=17982, start_index=17838, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=shape%20regulation.,the%20rounded%20morphology%20of%20acinar')
54. AnnotationURLCitation(end_index=18107, start_index=17983, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Par3,overgrowth%20of%20the%20acini%20and')
55. AnnotationURLCitation(end_index=18413, start_index=18289, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Par3,overgrowth%20of%20the%20acini%20and')
56. AnnotationURLCitation(end_index=18660, start_index=18536, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Par3,overgrowth%20of%20the%20acini%20and')
57. AnnotationURLCitation(end_index=18805, start_index=18661, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=were%20borderline%20hits,structure%20to%20the%20cell%20cycle')
58. AnnotationURLCitation(end_index=19268, start_index=19097, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=mutant%2C%20representing%20the%20first%20known,membranes%20are%20reduced%2C%20but%20not')
59. AnnotationURLCitation(end_index=19431, start_index=19269, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
60. AnnotationURLCitation(end_index=19996, start_index=19843, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=neurodegenerative%20disorders,functions%20in%20various%20aspects%20of')
61. AnnotationURLCitation(end_index=20174, start_index=19997, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=nervous%20system%20as%20well%20as,complexes%20in%20neuropsychiatric%20and%20neurodegenerative')
62. AnnotationURLCitation(end_index=20512, start_index=20359, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=neurodegenerative%20disorders,functions%20in%20various%20aspects%20of')
63. AnnotationURLCitation(end_index=20727, start_index=20513, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=migration%2C%20neurite%20differentiation%2C%20synaptic%20plasticity%2C,complexes%20in%20neuropsychiatric%20and%20neurodegenerative')
64. AnnotationURLCitation(end_index=21115, start_index=20962, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=neurodegenerative%20disorders,functions%20in%20various%20aspects%20of')
65. AnnotationURLCitation(end_index=21330, start_index=21116, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=migration%2C%20neurite%20differentiation%2C%20synaptic%20plasticity%2C,complexes%20in%20neuropsychiatric%20and%20neurodegenerative')
66. AnnotationURLCitation(end_index=21697, start_index=21572, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=Summary%20Predicted%20to%20be%20involved,Expression')
67. AnnotationURLCitation(end_index=21987, start_index=21862, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=Summary%20Predicted%20to%20be%20involved,Expression')
68. AnnotationURLCitation(end_index=22479, start_index=22354, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=Summary%20Predicted%20to%20be%20involved,Expression')
69. AnnotationURLCitation(end_index=23084, start_index=22959, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=Summary%20Predicted%20to%20be%20involved,Expression')
70. AnnotationURLCitation(end_index=23212, start_index=23085, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Subcellular%20summary,bound%20Rho%20small')
71. AnnotationURLCitation(end_index=23822, start_index=23718, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=PARD6B%20has%20been%20shown%20to,RHOQ')
72. AnnotationURLCitation(end_index=24523, start_index=24383, title='Cdc42, Par6, and aPKC regulate Arp2/3-mediated endocytosis to control local adherens junction stability - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18976918/#:~:text=Cdc42%2C%20Par6%2C%20and%20aPKC%20regulate,In%20this%20system')
73. AnnotationURLCitation(end_index=25229, start_index=25046, title='Cell polarity: the ups and downs of the Par6/aPKC complex - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S0959437X03000777#:~:text=Cell%20polarity%3A%20the%20ups%20and,polar%20granules%20to%20the%20posterior')
74. AnnotationURLCitation(end_index=26099, start_index=25931, title='Cell Signaling and Function Organized by PB1 Domain Interactions - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S1097276506005375#:~:text=ScienceDirect%20www,actin%20cytoskeleton%20and%20TJ%20dissolution')
75. AnnotationURLCitation(end_index=26415, start_index=26247, title='Cell Signaling and Function Organized by PB1 Domain Interactions - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S1097276506005375#:~:text=ScienceDirect%20www,actin%20cytoskeleton%20and%20TJ%20dissolution')
76. AnnotationURLCitation(end_index=26869, start_index=26701, title='Cell Signaling and Function Organized by PB1 Domain Interactions - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S1097276506005375#:~:text=ScienceDirect%20www,actin%20cytoskeleton%20and%20TJ%20dissolution')
77. AnnotationURLCitation(end_index=27573, start_index=27397, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=related%20signaling%20pathways%20and%20explored,the%20serine%20473%20phosphorylated%20status')
78. AnnotationURLCitation(end_index=27747, start_index=27574, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Maximal%20Akt%20activity%20requires%20phosphorylation,in%20the%20cells%20suffering%20loss')
79. AnnotationURLCitation(end_index=28085, start_index=27909, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=related%20signaling%20pathways%20and%20explored,the%20serine%20473%20phosphorylated%20status')
80. AnnotationURLCitation(end_index=28259, start_index=28086, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Maximal%20Akt%20activity%20requires%20phosphorylation,in%20the%20cells%20suffering%20loss')
81. AnnotationURLCitation(end_index=28579, start_index=28421, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=match%20at%20L532%20or%20PARD6G,partially%20rescued%20by%20inhibition%20of')
82. AnnotationURLCitation(end_index=28691, start_index=28580, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=PI3K%2FPDK1%2FAkt%20pathway')
83. AnnotationURLCitation(end_index=28933, start_index=28781, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=quiescent%20MCF10A%20structures,PAR%20complex%20activity%20and%20the')
84. AnnotationURLCitation(end_index=29408, start_index=29250, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=match%20at%20L532%20or%20PARD6G,partially%20rescued%20by%20inhibition%20of')
85. AnnotationURLCitation(end_index=29817, start_index=29649, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=match%20at%20L442%20related%20signaling,the%20serine%20473%20phosphorylated%20status')
86. AnnotationURLCitation(end_index=29956, start_index=29818, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=or%20PARD6G,partially%20rescued%20by%20inhibition%20of')
87. AnnotationURLCitation(end_index=30349, start_index=30211, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=or%20PARD6G,partially%20rescued%20by%20inhibition%20of')
88. AnnotationURLCitation(end_index=31003, start_index=30845, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=Neurodevelopment%20and%20in%20Neurodegenerative%20and,Author%20information')
89. AnnotationURLCitation(end_index=31457, start_index=31335, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=matrix.,PATJ%20and%20PAR%20formed%20by')
90. AnnotationURLCitation(end_index=31723, start_index=31601, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=matrix.,PATJ%20and%20PAR%20formed%20by')
91. AnnotationURLCitation(end_index=31868, start_index=31724, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=shape%20regulation.,the%20rounded%20morphology%20of%20acinar')
92. AnnotationURLCitation(end_index=32669, start_index=32502, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=The%20regulatory%20networks%20of%20cell,However%2C%20recent%20findings%20suggesting')
93. AnnotationURLCitation(end_index=33321, start_index=33142, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
94. AnnotationURLCitation(end_index=33474, start_index=33322, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=Contrary%20to%20the%20earlier%20findings%2C,MCF10A%20cells%20undergo')
95. AnnotationURLCitation(end_index=33774, start_index=33598, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=related%20signaling%20pathways%20and%20explored,the%20serine%20473%20phosphorylated%20status')
96. AnnotationURLCitation(end_index=33954, start_index=33775, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
97. AnnotationURLCitation(end_index=34465, start_index=34286, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
98. AnnotationURLCitation(end_index=34819, start_index=34640, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
99. AnnotationURLCitation(end_index=34990, start_index=34820, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=favor%20PAR6B%20upregulation%20and%20PAR6G,capacity%20of%20different%20PAR6%20proteins')
100. AnnotationURLCitation(end_index=35287, start_index=35163, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Par3,overgrowth%20of%20the%20acini%20and')
101. AnnotationURLCitation(end_index=35677, start_index=35525, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=Contrary%20to%20the%20earlier%20findings%2C,MCF10A%20cells%20undergo')
102. AnnotationURLCitation(end_index=35841, start_index=35678, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=could%20alone%20prevent%20the%20epithelial,PAR%20complex%20activity%20and%20the')
103. AnnotationURLCitation(end_index=36282, start_index=36106, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=related%20signaling%20pathways%20and%20explored,the%20serine%20473%20phosphorylated%20status')
104. AnnotationURLCitation(end_index=36456, start_index=36283, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Maximal%20Akt%20activity%20requires%20phosphorylation,in%20the%20cells%20suffering%20loss')
105. AnnotationURLCitation(end_index=36777, start_index=36648, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=monolayer%20culture,dependent%20proliferation')
106. AnnotationURLCitation(end_index=37252, start_index=37073, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
107. AnnotationURLCitation(end_index=37587, start_index=37432, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=status%20of%20PARD6B%20in%20cancer,in%20cancer%20genomics%20data%20sets')
108. AnnotationURLCitation(end_index=37732, start_index=37588, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=shape%20regulation.,the%20rounded%20morphology%20of%20acinar')
109. AnnotationURLCitation(end_index=38090, start_index=37911, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
110. AnnotationURLCitation(end_index=38889, start_index=38714, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Single%20cell%20type%20expression%20cluster,protein%20involved%20in%20asymmetrical%20cell')
111. AnnotationURLCitation(end_index=39598, start_index=39457, title='PARD6A', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6A#:~:text=A%20recent%20study%20shows%20that,which%20upregulate%20EMT%20in%20melanoma')
112. AnnotationURLCitation(end_index=40059, start_index=39918, title='PARD6A', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6A#:~:text=A%20recent%20study%20shows%20that,which%20upregulate%20EMT%20in%20melanoma')
113. AnnotationURLCitation(end_index=40350, start_index=40209, title='PARD6A', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6A#:~:text=A%20recent%20study%20shows%20that,which%20upregulate%20EMT%20in%20melanoma')
114. AnnotationURLCitation(end_index=41496, start_index=41372, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Par3,overgrowth%20of%20the%20acini%20and')
115. AnnotationURLCitation(end_index=42394, start_index=42223, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=mutant%2C%20representing%20the%20first%20known,membranes%20are%20reduced%2C%20but%20not')
116. AnnotationURLCitation(end_index=42959, start_index=42857, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=Aging,years%20old')
117. AnnotationURLCitation(end_index=43159, start_index=43057, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=Aging,years%20old')
118. AnnotationURLCitation(end_index=43734, start_index=43547, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=hormone%20level%20regulation%20and%20developmental,timing%20of%20critical%20physiological%20milestones')
119. AnnotationURLCitation(end_index=43908, start_index=43735, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=associated%20with%20tumorigenesis%20also%20exhibit,processes%20of%20aging%20and%20cancer')
120. AnnotationURLCitation(end_index=44537, start_index=44367, title='Frontiers | Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence', type='url_citation', url='https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1569122/abstract#:~:text=PARD6G,stage%20and%20lymph%20node%20metastasis')
121. AnnotationURLCitation(end_index=44696, start_index=44538, title='Frontiers | Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence', type='url_citation', url='https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1569122/abstract#:~:text=match%20at%20L413%20factors%20,013')
122. AnnotationURLCitation(end_index=45271, start_index=45070, title='Frontiers | Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence', type='url_citation', url='https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1569122/abstract#:~:text=al.%2C%202022%29.%20PARD6G,classical%20cancer%20driver%20signaling%20pathways')
123. AnnotationURLCitation(end_index=45736, start_index=45630, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Partitioning,in%20different')
124. AnnotationURLCitation(end_index=46063, start_index=45921, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=expression%20patterns%20of%20Par6%20isoforms,%CE%B2%20signaling')
125. AnnotationURLCitation(end_index=46448, start_index=46269, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
126. AnnotationURLCitation(end_index=46760, start_index=46638, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=matrix.,PATJ%20and%20PAR%20formed%20by')
127. AnnotationURLCitation(end_index=46925, start_index=46761, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=in%20this%20study%20encode%20proteins,Most%20cell%20cycle%20restriction%2Fgrowth')
128. AnnotationURLCitation(end_index=47333, start_index=47249, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=')
129. AnnotationURLCitation(end_index=47463, start_index=47334, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=monolayer%20culture,dependent%20proliferation')
130. AnnotationURLCitation(end_index=47784, start_index=47660, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=Par3,overgrowth%20of%20the%20acini%20and')
131. AnnotationURLCitation(end_index=47914, start_index=47785, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=monolayer%20culture,dependent%20proliferation')
132. AnnotationURLCitation(end_index=48156, start_index=48035, title='Polarity proteins in migration and invasion | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2008347#:~:text=Polarity%20proteins%20in%20migration%20and,%282004')
133. AnnotationURLCitation(end_index=49567, start_index=49380, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=hormone%20level%20regulation%20and%20developmental,timing%20of%20critical%20physiological%20milestones')
134. AnnotationURLCitation(end_index=49670, start_index=49568, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=Aging,years%20old')
135. AnnotationURLCitation(end_index=50288, start_index=50118, title='Frontiers | Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence', type='url_citation', url='https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1569122/abstract#:~:text=PARD6G,stage%20and%20lymph%20node%20metastasis')
136. AnnotationURLCitation(end_index=50870, start_index=50728, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=expression%20patterns%20of%20Par6%20isoforms,%CE%B2%20signaling')
137. AnnotationURLCitation(end_index=51241, start_index=51062, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
138. AnnotationURLCitation(end_index=51672, start_index=51493, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
139. AnnotationURLCitation(end_index=51843, start_index=51673, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=favor%20PAR6B%20upregulation%20and%20PAR6G,capacity%20of%20different%20PAR6%20proteins')
140. AnnotationURLCitation(end_index=52611, start_index=52460, title='Cell polarity proteins promote macropinocytosis in response to metabolic stress | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-54788-9#:~:text=Cell%20polarity%20proteins%20promote%20macropinocytosis,T560%7D%20levels')
141. AnnotationURLCitation(end_index=53241, start_index=53083, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=Neurodevelopment%20and%20in%20Neurodegenerative%20and,Author%20information')
142. AnnotationURLCitation(end_index=53395, start_index=53242, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=neurodegenerative%20disorders,functions%20in%20various%20aspects%20of')
143. AnnotationURLCitation(end_index=54069, start_index=53890, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
144. AnnotationURLCitation(end_index=54393, start_index=54214, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
145. AnnotationURLCitation(end_index=54814, start_index=54644, title='Frontiers | Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence', type='url_citation', url='https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1569122/abstract#:~:text=PARD6G,stage%20and%20lymph%20node%20metastasis')
146. AnnotationURLCitation(end_index=55324, start_index=55222, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=Aging,years%20old')
147. AnnotationURLCitation(end_index=55785, start_index=55643, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=expression%20patterns%20of%20Par6%20isoforms,%CE%B2%20signaling')
148. AnnotationURLCitation(end_index=56890, start_index=56784, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Partitioning,in%20different')
149. AnnotationURLCitation(end_index=57044, start_index=56891, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=neurodegenerative%20disorders,functions%20in%20various%20aspects%20of')
150. AnnotationURLCitation(end_index=57619, start_index=57494, title='PARD6G par-6 family cell polarity regulator gamma [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/84552#:~:text=Summary%20Predicted%20to%20be%20involved,Expression')
151. AnnotationURLCitation(end_index=57888, start_index=57741, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Predicted%20location,i%7D%20Cell%20cycle%2C%20Cell%20division')
152. AnnotationURLCitation(end_index=58016, start_index=57889, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Subcellular%20summary,bound%20Rho%20small')
153. AnnotationURLCitation(end_index=58242, start_index=58128, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=This%20gene%20is%20a%20member,protein%20complex')
154. AnnotationURLCitation(end_index=58347, start_index=58243, title='PARD6B', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6B#:~:text=PARD6B%20has%20been%20shown%20to,RHOQ')
155. AnnotationURLCitation(end_index=58688, start_index=58535, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=neurodegenerative%20disorders,functions%20in%20various%20aspects%20of')
156. AnnotationURLCitation(end_index=58866, start_index=58689, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9188383/#:~:text=nervous%20system%20as%20well%20as,complexes%20in%20neuropsychiatric%20and%20neurodegenerative')
157. AnnotationURLCitation(end_index=59149, start_index=58978, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=mutant%2C%20representing%20the%20first%20known,membranes%20are%20reduced%2C%20but%20not')
158. AnnotationURLCitation(end_index=59312, start_index=59150, title='Regulation of neurocoel morphogenesis by Pard6γb - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2626139/#:~:text=Pard6%CE%B3b%20function%20leads%20to%20defects,We%20found%20that%20Pard6%CE%B1')
159. AnnotationURLCitation(end_index=59656, start_index=59480, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=related%20signaling%20pathways%20and%20explored,the%20serine%20473%20phosphorylated%20status')
160. AnnotationURLCitation(end_index=59795, start_index=59657, title='Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4800288/#:~:text=or%20PARD6G,partially%20rescued%20by%20inhibition%20of')
161. AnnotationURLCitation(end_index=60060, start_index=59908, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=quiescent%20MCF10A%20structures,PAR%20complex%20activity%20and%20the')
162. AnnotationURLCitation(end_index=60240, start_index=60061, title='Par6 family proteins in cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4675776/#:~:text=of%20PAR6B%2C%20chromosomal%20gains%2C%20amplifications,PARD6B%20and%20PARD6G%20genes%20display')
163. AnnotationURLCitation(end_index=60485, start_index=60326, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Tissue%20specificity,brain%20regional%20specificity%20Cancer%20prognostic')
164. AnnotationURLCitation(end_index=60633, start_index=60486, title='PARD6G protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v21.proteinatlas.org/ENSG00000178184-PARD6G#:~:text=Predicted%20location,i%7D%20Cell%20cycle%2C%20Cell%20division')
165. AnnotationURLCitation(end_index=60835, start_index=60729, title='PARD6G Gene - GeneCards | PAR6G Protein | PAR6G Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=PARD6G#:~:text=UniProtKB%2FSwiss')
166. AnnotationURLCitation(end_index=60936, start_index=60836, title='PARD6G Gene - GeneCards | PAR6G Protein | PAR6G Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=PARD6G#:~:text=Function%3A')
167. AnnotationURLCitation(end_index=61195, start_index=61093, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=Aging,years%20old')
168. AnnotationURLCitation(end_index=61383, start_index=61196, title='Genome-Wide Integrative Transcriptional Profiling Identifies Age-Associated Signatures in Dogs - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10298135/#:~:text=hormone%20level%20regulation%20and%20developmental,timing%20of%20critical%20physiological%20milestones')
169. AnnotationURLCitation(end_index=61711, start_index=61541, title='Frontiers | Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence', type='url_citation', url='https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1569122/abstract#:~:text=PARD6G,stage%20and%20lymph%20node%20metastasis')
170. AnnotationURLCitation(end_index=61913, start_index=61712, title='Frontiers | Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence', type='url_citation', url='https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1569122/abstract#:~:text=al.%2C%202022%29.%20PARD6G,classical%20cancer%20driver%20signaling%20pathways')
171. AnnotationURLCitation(end_index=62173, start_index=62067, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Partitioning,in%20different')
172. AnnotationURLCitation(end_index=62316, start_index=62174, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=expression%20patterns%20of%20Par6%20isoforms,%CE%B2%20signaling')
173. AnnotationURLCitation(end_index=62562, start_index=62422, title='PARD6A', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6A#:~:text=%28CRIB%29%20domain,different%20isoforms%2C%20have%20been%20characterized')
174. AnnotationURLCitation(end_index=62704, start_index=62563, title='PARD6A', type='url_citation', url='https://en.wikipedia.org/wiki/PARD6A#:~:text=A%20recent%20study%20shows%20that,which%20upregulate%20EMT%20in%20melanoma')
175. AnnotationURLCitation(end_index=63092, start_index=62924, title='Cell Signaling and Function Organized by PB1 Domain Interactions - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S1097276506005375#:~:text=ScienceDirect%20www,actin%20cytoskeleton%20and%20TJ%20dissolution')
176. AnnotationURLCitation(end_index=63421, start_index=63300, title='Polarity proteins in migration and invasion | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2008347#:~:text=Polarity%20proteins%20in%20migration%20and,%282004')